Etravirine

6 ADVERSE REACTIONS The following adverse reactions are described in greater detail in other sections: Severe skin and hypersensitivity reactions [see Warnings and Precautions (5.1) ] . Immune reconstitution syndrome [see Warnings and Precautions (5.3) ] . The most common adverse drug reactions of moderate to severe intensity (at least 2%) which occurred at a higher rate than placebo in adults are rash and peripheral neuropathy. (6.1) The most common adverse drug reactions in at least 2% of pediatric patients are rash and diarrhea. (6.1) To report SUSPECTED ADVERSE REACTIONS, contact Amneal Pharmaceuticals at 1-877-835-5472 or FDA at 1-800-FDA-1088 or www.fda.gov/medwatch. 6.1 Clinical Trials Experience Because clinical trials are conducted under widely varying conditions, adverse reaction rates observed in the clinical trials of a drug cannot be directly compared to rates in the clinical trials of another drug and may not reflect the rates observed in practice. Clinical Trials Experience in Adults The safety assessment is based on all data from 1,203 subjects in the Phase 3 placebo-controlled trials, TMC125-C206 and TMC125-C216, conducted in antiretroviral treatment-experienced HIV-1-infected adult subjects, 599 of whom received etravirine (200 mg twice daily). In these pooled trials, the median exposure for subjects in the etravirine arm and placebo arm was 52.3 and 51.0 weeks, respectively. Discontinuations due to adverse drug reactions (ADRs) were 5.2% in the etravirine arm and 2.6% in the placebo arm. The most frequently reported ADR at least Grade 2 in severity was rash (10.0%). Stevens-Johnson syndrome, drug hypersensitivity reaction and erythema multiforme were reported in less than 0.1% of subjects during clinical development with etravirine [see Warnings and Precautions (5.1) ] . A total of 2.2% of HIV-1-infected subjects in Phase 3 trials receiving etravirine discontinued due to rash. In general, in clinical trials, rash was mild to moderate, occurred primarily in the second week of therapy, and was infrequent after Week 4. Rash generally resolved within 1 to 2 weeks on continued therapy. The incidence of rash was higher in women compared to men in the etravirine arm in the Phase 3 trials (rash ≥ Grade 2 was reported in 9/60 [15.0%] women versus 51/539 [9.5%] men; discontinuations due to rash were reported in 3/60 [5.0%] women versus 10/539 [1.9%] men) [see Warnings and Precautions (5.1) ] . Patients with a history of NNRTI-related rash did not appear to be at increased risk for the development of etravirine-related rash compared to patients without a history of NNRTI-related rash. Common Adverse Reactions Clinical ADRs of moderate intensity or greater (greater than or equal to Grade 2) and reported in at least 2% of subjects treated with etravirine and occurring at a higher rate compared to placebo (excess of 1%) are presented in Table 2. Laboratory abnormalities considered ADRs are included in Table 3. Table 2: Adverse Drug Reactions (Grades 2 to 4) in at Least 2% of Adult Subjects (Pooled TMC125-C206 and TMC125-C216 Trials) Preferred Term Etravirine + BR N=599 % Placebo + BR N=604 % Rash 10% 3% Peripheral neuropathy 4% 2% N=total number of subjects per treatment group; BR=background regimen Less Common Adverse Reactions Treatment-emergent ADRs occurring in less than 2% of subjects (599 subjects) receiving etravirine and of at least moderate intensity (greater than or equal to Grade 2) are listed below by body system: Cardiac Disorders : myocardial infarction, angina pectoris, atrial fibrillation Ear and Labyrinth Disorders : vertigo Eye Disorders : blurred vision Gastrointestinal Disorders : gastroesophageal reflux disease, flatulence, gastritis, abdominal distension, pancreatitis, constipation, dry mouth, hematemesis, retching, stomatitis General Disorders and Administration Site Conditions : sluggishness Hematologic Disorders : hemolytic anemia Hepatobiliary Disorders : hepatic failure, hepatomegaly, cytolytic hepatitis, hepatic steatosis, hepatitis Immune System Disorders : drug hypersensitivity, immune reconstitution syndrome Metabolism and Nutrition Disorders : diabetes mellitus, anorexia, dyslipidemia Nervous System Disorders : paresthesia, somnolence, convulsion, hypoesthesia, amnesia, syncope, disturbance in attention, hypersomnia, tremor Psychiatric Disorders : anxiety, sleep disorders, abnormal dreams, confusional state, disorientation, nervousness, nightmares Renal and Urinary Disorders: acute renal failure Reproductive System and Breast Disorders : gynecomastia Respiratory, Thoracic and Mediastinal Disorders : exertional dyspnea, bronchospasm Skin and Subcutaneous Tissue Disorders : night sweats, lipohypertrophy, prurigo, hyperhidrosis, dry skin, swelling face Additional ADRs of at least moderate intensity observed in other trials were acquired lipodystrophy, angioneurotic edema, erythema multiforme and hemorrhagic stroke, each reported in no more than 0.5% of subjects. Laboratory Abnormalities in Treatment-Experienced Patients Selected Grade 2 to Grade 4 laboratory abnormalities that represent a worsening from baseline observed in adult subjects treated with etravirine are presented in Table 3. Table 3: Selected Grade 2 to 4 Laboratory Abnormalities Observed in Treatment-Experienced Subjects (Pooled TMC125-C206 and TMC125-C216 Trials) Laboratory Parameter DAIDS Toxicity Range Etravirine + BR N=599 % Placebo + BR N=604 % GENERAL BIOCHEMISTRY Pancreatic amylase Grade 2 > 1.5 to 2 x ULN 7% 8% Grade 3 > 2 to 5 x ULN 7% 8% Grade 4 > 5 x ULN 2% 1% Lipase Grade 2 > 1.5 to 3 x ULN 4% 6% Grade 3 > 3 to 5 x ULN 2% 2% Grade 4 > 5 x ULN 1% < 1% Creatinine Grade 2 > 1.4 to 1.8 x ULN 6% 5% Grade 3 > 1.9 to 3.4 x ULN 2% 1% Grade 4 > 3.4 x ULN 0% < 1% HEMATOLOGY Decreased hemoglobin Grade 2 90 g/L to 99 g/L 2% 4% Grade 3 70 g/L to 89 g/L < 1% < 1% Grade 4 < 70 g/L < 1% < 1% White blood cell count Grade 2 1,500 to 1,999/mm 3 2% 3% Grade 3 1,000 to 1,499/mm 3 1% 4% Grade 4 < 1,000/mm 3 1% < 1% Neutrophils Grade 2 750 to 999/mm 3 5% 6% Grade 3 500 to 749/mm 3 4% 4% Grade 4 < 500/mm 3 2% 3% Platelet count Grade 2 50,000 to 99,999/mm 3 3% 5% Grade 3 25,000 to 49,999/mm 3 1% 1% Grade 4 < 25,000/mm 3 < 1% < 1% LIPIDS AND GLUCOSE Total cholesterol Grade 2 > 6.20 to 7.77 mmol/L 240 to 300 mg/dL 20% 17% Grade 3 > 7.77 mmol/L > 300 mg/dL 8% 5% Low density lipoprotein Grade 2 4.13 to 4.9 mmol/L 160 to 190 mg/dL 13% 12% Grade 3 > 4.9 mmol/L > 190 mg/dL 7% 7% Triglycerides Grade 2 5.65 to 8.48 mmol/L 500 to 750 mg/dL 9% 7% Grade 3 8.49 to 13.56 mmol/L 751 to 1,200 mg/dL 6% 4% Grade 4 > 13.56 mmol/L > 1200 mg/dL 4% 2% Elevated glucose levels Grade 2 6.95 to 13.88 mmol/L 161 to 250 mg/dL 15% 13% Grade 3 13.89 to 27.75 mmol/L 251 to 500 mg/dL 4% 2% Grade 4 > 27.75 mmol/L > 500 mg/dL 0% < 1% HEPATIC PARAMETERS Alanine amino transferase Grade 2 2.6 to 5 x ULN 6% 5% Grade 3 5.1 to 10 x ULN 3% 2% Grade 4 > 10 x ULN 1% < 1% Aspartate amino transferase Grade 2 2.6 to 5 x ULN 6% 8% Grade 3 5.1 to 10 x ULN 3% 2% Grade 4 > 10 x ULN < 1% < 1% ULN=Upper Limit of Normal; BR=background regimen Patients Co-Infected With Hepatitis B and/or Hepatitis C Virus In Phase 3 trials TMC125-C206 and TMC125-C216, 139 subjects (12.3%) with chronic hepatitis B and/or hepatitis C virus co-infection out of 1,129 subjects were permitted to enroll. AST and ALT abnormalities occurred more frequently in hepatitis B and/or hepatitis C virus co-infected subjects for both treatment groups. Grade 2 or higher laboratory abnormalities that represent a worsening from baseline of AST, ALT or total bilirubin occurred in 27.8%, 25.0% and 7.1% respectively, of etravirine-treated co-infected subjects as compared to 6.7%, 7.5% and 1.8% of non-co-infected etravirine-treated subjects. In general, adverse events reported by etravirine-treated subjects with hepatitis B and/or hepatitis C virus co-infection were similar to etravirine-treated subjects without hepatitis B and/or hepatitis C virus co-infection. Clinical Trials Experience in Pediatric Subjects (6 Years to Less Than 18 years of age) The safety assessment in pediatric subjects is based on a single-arm trial. TMC125-C213 is a Phase 2 trial in which 101 antiretroviral treatment-experienced HIV-1 infected pediatric subjects 6 years to less than 18 years of age received etravirine in combination with other antiretroviral agents (Week 24 analysis) [see Clinical Studies (14.2) ] . In TMC125-C213, the frequency, type and severity of adverse drug reactions in pediatric subjects 6 years to less than 18 years of age were comparable to those observed in adult subjects, except for rash which was observed more frequently in pediatric subjects. The most common adverse drug reactions in at least 2% of pediatric subjects were rash and diarrhea. Rash was reported more frequently in female subjects than in male subjects (rash ≥ Grade 2 was reported in 13/64 [20.3%] females versus 2/37 [5.4%] males; discontinuations due to rash were reported in 4/64 [6.3%] females versus 0/37 [0%] males). Rash (greater than or equal to Grade 2) occurred in 15% of pediatric subjects from 6 years to less than 18 years of age. In the majority of cases, rash was mild to moderate, of macular/papular type, and occurred in the second week of therapy. Rash was self-limiting and generally resolved within 1 week on continued therapy. The safety profile for subjects who completed 48 weeks of treatment was similar to the safety profile for subjects who completed 24 weeks of treatment. Additional pediatric use information is approved for Janssen Products, LP’s INTELENCE ® (etravirine) tablets. However, due to Janssen Products, LP’s marketing exclusivity rights, this drug product is not labeled with that pediatric information. 6.2 Postmarketing Experience The following events have been identified during postmarketing use of etravirine. Because these events are reported voluntarily from a population of unknown size, it is not always possible to reliably estimate their frequency or establish a causal relationship to drug exposure. Immune System Disorders : Severe hypersensitivity reactions including DRESS and cases of hepatic failure have been reported [see Warnings and Precautions (5.1) ] . Musculoskeletal and Connective Tissue Disorders : rhabdomyolysis Skin and Subcutaneous Tissue Disorders : Fatal cases of toxic epidermal necrolysis and Stevens-Johnson syndrome have been reported [see Warnings and Precautions (5.1) ] .

4 CONTRAINDICATIONS None. None. (4)

11 DESCRIPTION Etravirine is a non-nucleoside reverse transcriptase inhibitor (NNRTI) of human immunodeficiency virus type 1 (HIV-1). The chemical name for etravirine is 4-[[6-amino-5-bromo-2-[(4-cyanophenyl) amino]-4-pyrimidinyl] oxy]-3,5-dimethylbenzonitrile. Its molecular formula is C 20 H 15 BrN 6 O and its molecular weight is 435.28 g/mol. Etravirine has the following structural formula: Etravirine is a white to slightly yellowish-brown powder. Etravirine is practically insoluble in water and freely soluble in some organic solvents like N,N-dimethylformamide and tetrahydrofuran. Etravirine tablets are for oral administration. Each etravirine tablet contains 25 mg, 100 mg or 200 mg of etravirine. It also contains the inactive ingredients: croscarmellose sodium, crospovidone (type A), colloidal silicon dioxide, hypromellose, low-substituted hydroxy propyl cellulose, magnesium stearate and microcrystalline cellulose. chemical structure

2 DOSAGE AND ADMINISTRATION Adult patients: 200 mg (one 200 mg tablet or two 100 mg tablets) taken twice daily following a meal. (2.1 , 2.2 , 2.4) Pregnant patients: 200 mg (one 200 mg tablet or two 100 mg tablets) taken twice daily following a meal. (2.2) Pediatric patients (6 years to less than 18 years of age and weighing at least 16 kg): dosage of etravirine tablets are based on body weight and should not exceed the recommended adult dose. Etravirine tablets should be taken following a meal. (2.3) 2.1 Recommended Dosage in Adult Patients The recommended oral dosage of etravirine tablets for adult patients is 200 mg (one 200 mg tablet or two 100 mg tablets) taken twice daily following a meal. The type of food does not affect the exposure to etravirine [see Clinical Pharmacology (12.3) ] . 2.2 Recommended Dosage During Pregnancy The recommended oral dosage of etravirine tablets for pregnant individuals is 200 mg (one 200 mg tablet or two 100 mg tablets) taken twice daily following a meal [see Use in Specific Populations (8.1) ] . 2.3 Recommended Dosage in Pediatric Patients (6 Years to Less Than 18 Years of Age) The recommended dosage of etravirine tablets for pediatric patients 6 years to less than 18 years of age and weighing at least 16 kg is based on body weight (see Table 1) not exceeding the recommended adult dosage. Etravirine tablets should be taken orally, following a meal. The type of food does not affect the exposure to etravirine tablets [see Clinical Pharmacology (12.3) ] . Table 1: Recommended Dosage of Etravirine Tablets for Pediatric Patients 6 Years to Less Than 18 Years of Age Body Weight kilograms (kg) Dose greater than or equal to 16 kg to less than 20 kg 100 mg twice daily greater than or equal to 20 kg to less than 25 kg 125 mg twice daily greater than or equal to 25 kg to less than 30 kg 150 mg twice daily greater than or equal to 30 kg 200 mg twice daily Additional pediatric use information is approved for Janssen Products, LP’s INTELENCE ® (etravirine) tablets. However, due to Janssen Products, LP’s marketing exclusivity rights, this drug product is not labeled with that pediatric information. 2.4 Method of Administration Instruct patients to swallow the etravirine tablet(s) whole with liquid such as water. Patients who are unable to swallow the etravirine tablet(s) whole may disperse the tablet(s) in water. Instruct the patient to do the following: place the tablet(s) in 5 mL (1 teaspoon) of water, or at least enough liquid to cover the medication, stir well until the water looks milky, add approximately 15 mL (1 tablespoon) of liquid. Water may be used but other liquids, such as orange juice or milk, may improve taste. Patients should not place the tablets in orange juice or milk without first adding water. The use of warm (temperature greater than 104°F [greater than 40°C]) or carbonated beverages should be avoided. drink the mixture immediately, rinse the glass several times with orange juice, milk or water and completely swallow the rinse each time to make sure the patient takes the entire dose.

1 INDICATIONS AND USAGE Etravirine tablets, in combination with other antiretroviral agents, are indicated for the treatment of human immunodeficiency virus type 1 (HIV-1) infection in antiretroviral treatment-experienced adult patients and pediatric patients 6 years of age and older [see Microbiology (12.4) and Clinical Studies (14) ] . Additional pediatric use information is approved for Janssen Products, LP’s INTELENCE ® (etravirine) tablets. However, due to Janssen Products, LP’s marketing exclusivity rights, this drug product is not labeled with that pediatric information. Etravirine is a human immunodeficiency virus type 1 (HIV-1) non-nucleoside reverse transcriptase inhibitor (NNRTI) indicated for treatment of HIV-1 infection in treatment-experienced patients 6 years of age and older. (1)

10 OVERDOSAGE There is no specific antidote for overdose with etravirine. Human experience of overdose with etravirine is limited. The highest dose studied in healthy volunteers was 400 mg once daily. Treatment of overdose with etravirine consists of general supportive measures including monitoring of vital signs and observation of the clinical status of the patient. Because etravirine is highly protein bound, dialysis is unlikely to result in significant removal of the active substance.

7 DRUG INTERACTIONS Co-administration of etravirine with other drugs can alter the concentrations of other drugs and other drugs may alter the concentrations of etravirine. The potential drug-drug interactions must be considered prior to and during therapy. (7 , 12.3) 7.1 Potential for Other Drugs to Affect Etravirine Etravirine is a substrate of CYP3A, CYP2C9, and CYP2C19. Therefore, co-administration of etravirine with drugs that induce or inhibit CYP3A, CYP2C9, and CYP2C19 may alter the therapeutic effect or adverse reaction profile of etravirine (see Table 4) [see Clinical Pharmacology (12.3) ]. 7.2 Potential for Etravirine to Affect Other Drugs Etravirine is an inducer of CYP3A and inhibitor of CYP2C9, CYP2C19 and P-glycoprotein (P-gp). Therefore, co-administration of drugs that are substrates of CYP3A, CYP2C9 and CYP2C19 or are transported by P-gp with etravirine may alter the therapeutic effect or adverse reaction profile of the co-administered drug(s) (see Table 4) [see Clinical Pharmacology (12.3) ]. 7.3 Significant Drug Interactions Table 4 shows significant drug interactions based on which, alterations in dose or regimen of etravirine and/or co-administered drug may be recommended. Drugs that are not recommended for co-administration with etravirine are also included in Table 4 [see Clinical Pharmacology (12.3) ] . Table 4: Significant Drug Interactions Concomitant Drug Class: Drug Name Effect on Concentration of Etravirine or Concomitant Drug Clinical Comment HIV-antiviral agents: integrase strand inhibitors dolutegravir* ↓ dolutegravir ↔ etravirine Etravirine significantly reduced plasma concentrations of dolutegravir. Using cross-study comparisons to historical pharmacokinetic data for etravirine, dolutegravir did not appear to affect the pharmacokinetics of etravirine. dolutegravir/darunavir/ritonavir* ↓ dolutegravir ↔ etravirine The effect of etravirine on dolutegravir plasma concentrations was mitigated by co-administration of darunavir/ritonavir or lopinavir/ritonavir, and is expected to be mitigated by atazanavir/ritonavir. dolutegravir/lopinavir/ritonavir* ↔ dolutegravir ↔ etravirine Dolutegravir should only be used with etravirine when co-administered with atazanavir/ritonavir, darunavir/ritonavir, or lopinavir/ritonavir. HIV-antiviral agents: non-nucleoside reverse transcriptase inhibitors (NNRTIs) efavirenz* nevirapine* ↓ etravirine Combining two NNRTIs has not been shown to be beneficial. Concomitant use of etravirine with efavirenz or nevirapine may cause a significant decrease in the plasma concentrations of etravirine and loss of therapeutic effect of etravirine. Co-administration of etravirine and other NNRTIs is not recommended. delavirdine ↑ etravirine Combining two NNRTIs has not been shown to be beneficial. Etravirine and delavirdine should not be co-administered. rilpivirine ↓ rilpivirine ↔ etravirine Combining two NNRTIs has not been shown to be beneficial. Co-administration of etravirine and rilpivirine is not recommended. HIV-antiviral agents: protease inhibitors (PIs) atazanavir* (without ritonavir) ↓ atazanavir Co-administration of etravirine and atazanavir without low-dose ritonavir is not recommended. atazanavir/ritonavir* ↓ atazanavir ↔ etravirine Concomitant use of etravirine with atazanavir/ritonavir decreased atazanavir C min but it is not considered clinically relevant. The mean systemic exposure (AUC) of etravirine after co-administration of etravirine with atazanavir/ritonavir in HIV-infected subjects was similar to the mean systemic exposure of etravirine observed in the Phase 3 trials after co-administration of etravirine and darunavir/ritonavir (as part of the background regimen). Etravirine and atazanavir/ritonavir can be co-administered without dose adjustments. atazanavir/cobicistat ↓ atazanavir ↓ cobicistat Co-administration of etravirine with atazanavir/cobicistat is not recommended because it may result in loss of therapeutic effect and development of resistance to atazanavir. darunavir/ritonavir* ↓ etravirine The mean systemic exposure (AUC) of etravirine was reduced when etravirine was co-administered with darunavir/ritonavir. Because all subjects in the Phase 3 trials received darunavir/ritonavir as part of the background regimen and etravirine exposures from these trials were determined to be safe and effective, etravirine and darunavir/ritonavir can be co-administered without dose adjustments. darunavir/cobicistat ↓ cobicistat darunavir: effect unknown Co-administration of etravirine with darunavir/cobicistat is not recommended because it may result in loss of therapeutic effect and development of resistance to darunavir. fosamprenavir (without ritonavir) ↑ amprenavir Concomitant use of etravirine with fosamprenavir without low-dose ritonavir may cause a significant alteration in the plasma concentration of amprenavir. Co-administration of etravirine and fosamprenavir without low-dose ritonavir is not recommended. fosamprenavir/ritonavir* ↑ amprenavir Due to a significant increase in the systemic exposure of amprenavir, the appropriate doses of the combination of etravirine and fosamprenavir/ritonavir have not been established. Co-administration of etravirine and fosamprenavir/ritonavir is not recommended. indinavir* (without ritonavir) ↓ indinavir Concomitant use of etravirine with indinavir without low-dose ritonavir may cause a significant alteration in the plasma concentration of indinavir. Co-administration of etravirine and indinavir without low-dose ritonavir is not recommended. lopinavir/ritonavir* ↓ etravirine The mean systemic exposure (AUC) of etravirine was reduced after co-administration of etravirine with lopinavir/ritonavir (tablet). Because the reduction in the mean systemic exposures of etravirine in the presence of lopinavir/ritonavir is similar to the reduction in mean systemic exposures of etravirine in the presence of darunavir/ritonavir, etravirine and lopinavir/ritonavir can be co-administered without dose adjustments. nelfinavir (without ritonavir) ↑ nelfinavir Concomitant use of etravirine with nelfinavir without low-dose ritonavir may cause a significant alteration in the plasma concentration of nelfinavir. Co-administration of etravirine and nelfinavir without low-dose ritonavir is not recommended. ritonavir* ↓ etravirine Concomitant use of etravirine with ritonavir 600 mg twice daily may cause a significant decrease in the plasma concentration of etravirine and loss of therapeutic effect of etravirine. Co-administration of etravirine and ritonavir 600 mg twice daily is not recommended. saquinavir/ritonavir* ↓ etravirine The mean systemic exposure (AUC) of etravirine was reduced when etravirine was co-administered with saquinavir/ritonavir. Because the reduction in the mean systemic exposures of etravirine in the presence of saquinavir/ritonavir is similar to the reduction in mean systemic exposures of etravirine in the presence of darunavir/ritonavir, etravirine and saquinavir/ritonavir can be co-administered without dose adjustments. tipranavir/ritonavir* ↓ etravirine Concomitant use of etravirine with tipranavir/ritonavir may cause a significant decrease in the plasma concentrations of etravirine and loss of therapeutic effect of etravirine. Co-administration of etravirine and tipranavir/ritonavir is not recommended. CCR5 antagonists maraviroc* ↔ etravirine ↓ maraviroc When etravirine is co-administered with maraviroc in the absence of a potent CYP3A inhibitor (e.g., ritonavir boosted protease inhibitor), the recommended dose of maraviroc is 600 mg twice daily. No dose adjustment of etravirine is needed. maraviroc/darunavir/ritonavir* † ↔ etravirine ↑ maraviroc When etravirine etravirine is co-administered with maraviroc in the presence of a potent CYP3A inhibitor (e.g., ritonavir boosted protease inhibitor), the recommended dose of maraviroc is 150 mg twice daily. No dose adjustment of etravirine is needed. Other agents Antiarrhythmics : digoxin* ↔ etravirine ↑ digoxin For patients who are initiating a combination of etravirine and digoxin, the lowest dose of digoxin should initially be prescribed. For patients on a stable digoxin regimen and initiating etravirine, no dose adjustment of either etravirine or digoxin is needed. The serum digoxin concentrations should be monitored and used for titration of the digoxin dose to obtain the desired clinical effect. amiodarone bepridil disopyramide flecainide lidocaine (systemic) mexiletine propafenone quinidine ↓ antiarrhythmics Concentrations of these antiarrhythmics may be decreased when co-administered with etravirine. Etravirine and antiarrhythmics should be co-administered with caution. Drug concentration monitoring is recommended, if available. Anticoagulant : warfarin ↑ anticoagulants Warfarin concentrations may be increased when co-administered with etravirine. The international normalized ratio (INR) should be monitored when warfarin is combined with etravirine. Anticonvulsants : carbamazepine phenobarbital phenytoin ↓ etravirine Carbamazepine, phenobarbital and phenytoin are inducers of CYP450 enzymes. Etravirine should not be used in combination with carbamazepine, phenobarbital, or phenytoin as co-administration may cause significant decreases in etravirine plasma concentrations and loss of therapeutic effect of etravirine. Antifungals : fluconazole* ↑ etravirine ↔ fluconazole Co-administration of etravirine and fluconazole significantly increased etravirine exposures. The amount of safety data at these increased etravirine exposures is limited, therefore, etravirine and fluconazole should be co-administered with caution. No dose adjustment of etravirine or fluconazole is needed. voriconazole* ↑ voriconazole Co-administration of etravirine and voriconazole significantly increased etravirine exposures. The amount of safety data at these increased etravirine exposures is limited, therefore, etravirine and voriconazole should be co-administered with caution. No dose adjustment of etravirine or voriconazole is needed. Antifungals : itraconazole ketoconazole posaconazole ↑ etravirine ↓ itraconazole ↓ ketoconazole ↔ posaconazole Posaconazole, a potent inhibitor of CYP3A4, may increase plasma concentrations of etravirine. Itraconazole and ketoconazole are potent inhibitors as well as substrates of CYP3A4. Concomitant systemic use of itraconazole or ketoconazole and etravirine may increase plasma concentrations of etravirine. Simultaneously, plasma concentrations of itraconazole or ketoconazole may be decreased by etravirine. Dose adjustments for itraconazole, ketoconazole or posaconazole may be necessary depending on the other co-administered drugs. Antiinfective : clarithromycin* ↑ etravirine ↓ clarithromycin ↑ 14-OH-clarithromycin Clarithromycin exposure was decreased by etravirine; however, concentrations of the active metabolite, 14-hydroxy-clarithromycin, were increased. Because 14-hydroxy-clarithromycin has reduced activity against Mycobacterium avium complex (MAC), overall activity against this pathogen may be altered. Alternatives to clarithromycin, such as azithromycin, should be considered for the treatment of MAC. Antimalarial : artemether/lumefantrine* ↔ etravirine ↓ artemether ↓ dihydroartemisinin ↓ lumefantrine Caution is warranted when co-administering etravirine and artemether/lumefantrine as it is unknown whether the decrease in exposure of artemether or its active metabolite, dihydroartemisinin, could result in decreased antimalarial efficacy. No dose adjustment is needed for etravirine. Antimycobacterials: rifampin rifapentine ↓ etravirine Rifampin and rifapentine are potent inducers of CYP450 enzymes. Etravirine should not be used with rifampin or rifapentine as co-administration may cause significant decreases in etravirine plasma concentrations and loss of therapeutic effect of etravirine. Antimycobacterial: rifabutin* ↓ etravirine ↓ rifabutin ↓ 25- O -desacetylrifabutin If etravirine is NOT co-administered with a protease inhibitor/ritonavir, then rifabutin at a dose of 300 mg once daily is recommended. If etravirine is co-administered with darunavir/ritonavir, lopinavir/ritonavir or saquinavir/ritonavir, then rifabutin should not be co-administered due to the potential for significant reductions in etravirine exposure. Benzodiazepine: diazepam ↑ diazepam Concomitant use of etravirine with diazepam may increase plasma concentrations of diazepam. A decrease in diazepam dose may be needed. Corticosteroid : dexamethasone (systemic) ↓ etravirine Systemic dexamethasone induces CYP3A and can decrease etravirine plasma concentrations. This may result in loss of therapeutic effect of etravirine. Systemic dexamethasone should be used with caution or alternatives should be considered, particularly for long-term use. Herbal products : St. John's wort ( Hypericum perforatum ) ↓ etravirine Concomitant use of etravirine with products containing St. John’s wort may cause significant decreases in etravirine plasma concentrations and loss of therapeutic effect of etravirine. Etravirine and products containing St. John’s wort should not be co-administered. Hepatitis C virus (HCV) direct-acting antivirals : daclatasvir ↓ daclatasvir Co-administration of etravirine with daclatasvir may decrease daclatasvir concentrations. Increase the daclatasvir dose to 90 mg once daily. elbasvir/grazoprevir ↓ elbasvir ↓ grazoprevir Co-administration of etravirine with elbasvir/grazoprevir may decrease elbasvir and grazoprevir concentrations, leading to reduced therapeutic effect of elbasvir/grazoprevir. Co-administration is not recommended. simeprevir ↓ simeprevir Co-administration of etravirine with simeprevir may decrease simeprevir concentrations. Co-administration is not recommended. HMG-CoA reductase inhibitors : atorvastatin* ↔ etravirine ↓ atorvastatin ↑ 2-OH-atorvastatin The combination of etravirine and atorvastatin can be given without dose adjustments, however, the dose of atorvastatin may need to be altered based on clinical response. pravastatin rosuvastatin ↔ etravirine ↔ pravastatin ↔ rosuvastatin No interaction between pravastatin, rosuvastatin and etravirine is expected. lovastatin simvastatin ↓ lovastatin ↓ simvastatin Lovastatin and simvastatin are CYP3A substrates and co-administration with etravirine may result in lower plasma concentrations of the HMG-CoA reductase inhibitor. fluvastatin pitavastatin ↑ fluvastatin ↑ pitavastatin Fluvastatin and pitavastatin are metabolized by CYP2C9 and co-administration with etravirine may result in higher plasma concentrations of the HMG-CoA reductase inhibitor. Dose adjustments for these HMG-CoA reductase inhibitors may be necessary. Immunosuppressants : cyclosporine sirolimus tacrolimus ↓ immunosuppressant Etravirine and systemic immunosuppressants should be co-administered with caution because plasma concentrations of cyclosporine, sirolimus, or tacrolimus may be affected. Narcotic analgesics/treatment of opioid dependence: buprenorphine buprenorphine/naloxone* methadone* ↔ etravirine ↓ buprenorphine ↔ norbuprenorphine ↔ methadone Etravirine and buprenorphine (or buprenorphine/naloxone) can be co-administered without dose adjustments, however, clinical monitoring for withdrawal symptoms is recommended as buprenorphine (or buprenorphine/naloxone) maintenance therapy may need to be adjusted in some patients. Etravirine and methadone can be co-administered without dose adjustments, however, clinical monitoring for withdrawal symptoms is recommended as methadone maintenance therapy may need to be adjusted in some patients. Phosphodiesterase type 5 (PDE-5) inhibitors : sildenafil* tadalafil vardenafil ↓ sildenafil ↓ N-desmethyl-sildenafil Etravirine and sildenafil can be co-administered without dose adjustments, however, the dose of sildenafil may need to be altered based on clinical effect. Platelet aggregation inhibitors: clopidogrel ↓ clopidogrel (active) metabolite Activation of clopidogrel to its active metabolite may be decreased when clopidogrel is co-administered with etravirine. Alternatives to clopidogrel should be considered. ↑ = increase; ↓ = decrease; ↔ = no change * The interaction between etravirine and the drug was evaluated in a clinical study. All other drug interactions shown are predicted. † The reference for etravirine exposure is the pharmacokinetic parameters of etravirine in the presence of darunavir/ritonavir. 7.4 Drugs Without Clinically Significant Interactions with Etravirine In addition to the drugs included in Table 4, the interaction between etravirine and the following drugs were evaluated in clinical studies and no dose adjustment is needed for either drug [see Clinical Pharmacology (12.3) ] : didanosine, enfuvirtide (ENF), ethinylestradiol/norethindrone, omeprazole, paroxetine, raltegravir, ranitidine, and tenofovir disoproxil fumarate.

12 CLINICAL PHARMACOLOGY 12.1 Mechanism of Action Etravirine is an antiretroviral drug [see Microbiology (12.4) ] . 12.2 Pharmacodynamics Cardiac Electrophysiology In a thorough QT/QTc study in 41 healthy subjects, etravirine 200 mg twice daily or 400 mg once daily did not affect the QT/QTc interval. 12.3 Pharmacokinetics The pharmacokinetic properties of etravirine were determined in healthy adult subjects and in treatment-experienced HIV-1-infected adult and pediatric subjects. The systemic exposures (AUC) to etravirine were lower in HIV-1-infected subjects (Table 5) than in healthy subjects. Table 5: Population Pharmacokinetic Estimates of Etravirine 200 mg Twice Daily in HIV-1-Infected Adult Subjects (Integrated Data from Phase 3 Trials at Week 48) * Parameter Etravirine N=575 AUC 12h (ng•h/mL) Geometric mean ± standard deviation 4,522 ± 4,710 Median (range) 4,380 (458 to 59,084) C 0h (ng/mL) Geometric mean ± standard deviation 297 ± 391 Median (range) 298 (2 to 4,852) * All HIV-1-infected subjects enrolled in Phase 3 clinical trials received darunavir/ritonavir 600/100 mg twice daily as part of their background regimen. Therefore, the pharmacokinetic parameter estimates shown in Table 5 account for reductions in the pharmacokinetic parameters of etravirine due to co-administration of etravirine with darunavir/ritonavir. Note: The median protein binding adjusted EC 50 for MT4 cells infected with HIV-1/IIIB in vitro equals 4 ng/mL. Absorption and Bioavailability Following oral administration, etravirine was absorbed with a T max of about 2.5 to 4 hours. The absolute oral bioavailability of etravirine is unknown. In healthy subjects, the absorption of etravirine is not affected by co-administration of oral ranitidine or omeprazole, drugs that increase gastric pH. Effects of Food on Oral Absorption The systemic exposure (AUC) to etravirine was decreased by about 50% when etravirine tablet was administered under fasting conditions, as compared to when etravirine tablet was administered following a meal. Within the range of meals studied, the systemic exposures to etravirine were similar. The total caloric content of the various meals evaluated ranged from 345 kilocalories (17 grams fat) to 1,160 kilocalories (70 grams fat). Distribution Etravirine is about 99.9% bound to plasma proteins, primarily to albumin (99.6%) and alpha 1-acid glycoprotein (97.66% to 99.02%) in vitro . The distribution of etravirine into compartments other than plasma (e.g., cerebrospinal fluid, genital tract secretions) has not been evaluated in humans. Metabolism In vitro experiments with human liver microsomes (HLMs) indicate that etravirine primarily undergoes metabolism by CYP3A, CYP2C9, and CYP2C19 enzymes. The major metabolites, formed by methyl hydroxylation of the dimethylbenzonitrile moiety, were at least 90% less active than etravirine against wild-type HIV in cell culture. Elimination After single dose oral administration of 800 mg 14 C-etravirine, 93.7% and 1.2% of the administered dose of 14 C-etravirine was recovered in the feces and urine, respectively. Unchanged etravirine accounted for 81.2% to 86.4% of the administered dose in feces. Unchanged etravirine was not detected in urine. The mean (± standard deviation) terminal elimination half-life of etravirine was about 41 (± 20) hours. Specific Populations Geriatric Patients Population pharmacokinetic analysis in HIV-infected subjects showed that etravirine pharmacokinetics are not considerably different within the age range (18 to 77 years) evaluated [see Use in Specific Populations (8.5) ] . Pediatric Patients The pharmacokinetics of etravirine in 101 treatment-experienced HIV-1-infected pediatric subjects, 6 years to less than 18 years of age showed that the administered weight-based dosages resulted in etravirine exposure comparable to that in adults receiving etravirine 200 mg twice daily [see Dosage and Administration (2.3) ] . The pharmacokinetic parameters for etravirine (AUC 12h and C 0h ) are summarized in Table 6. Table 6: Pharmacokinetic Parameters for Etravirine in Treatment-Experienced HIV-1-Infected Pediatric Subjects 6 Years to Less Than 18 Years of Age (TMC125-C213 [Population PK]) Study TMC125-C213 Age Range (years) (6 years to less than 18 years) Parameter N=101 AUC 12h (ng•h/mL) Geometric mean ± standard deviation 3,742 ± 4,314 Median (range) 4,499 (62 to 28,865) C 0h (ng/mL) Geometric mean ± standard deviation 205 ± 342 Median (range) 287 (2 to 2,276) The pharmacokinetics and dose of etravirine in pediatric subjects less than 2 years of age have not been established [see Use in Specific Populations (8.4) ]. Additional pediatric use information is approved for Janssen Products, LP’s INTELENCE ® (etravirine) tablets. However, due to Janssen Products, LP’s marketing exclusivity rights, this drug product is not labeled with that pediatric information. Male and Female Patients No significant pharmacokinetic differences have been observed between males and females. Racial or Ethnic Groups Population pharmacokinetic analysis of etravirine in HIV-infected subjects did not show an effect of race on exposure to etravirine. Patients with Renal Impairment The pharmacokinetics of etravirine have not been studied in patients with renal impairment. The results from a mass balance study with 14 C-etravirine showed that less than 1.2% of the administered dose of etravirine is excreted in the urine as metabolites. No unchanged drug was detected in the urine. As etravirine is highly bound to plasma proteins, it is unlikely that it will be significantly removed by hemodialysis or peritoneal dialysis [see Use in Specific Populations (8.7) ] . Patients with Hepatic Impairment Etravirine is primarily metabolized by the liver. The steady-state pharmacokinetic parameters of etravirine were similar after multiple dose administration of etravirine to subjects with normal hepatic function (16 subjects), mild hepatic impairment (Child-Pugh Class A, 8 subjects), and moderate hepatic impairment (Child-Pugh Class B, 8 subjects). The effect of severe hepatic impairment on the pharmacokinetics of etravirine has not been evaluated [see Use in Specific Populations (8.6) ] . Pregnancy and Postpartum After intake of etravirine 200 mg twice daily in combination with other antiretroviral agents (13 subjects with 2 NRTIs, 1 subject with 2 NRTIs + lopinavir + ritonavir, 1 subject with 2 NRTIs + raltegravir), based on intra-individual comparison, the C max and AUC 12h of total etravirine were 23% to 42% higher during pregnancy compared with postpartum (6 to 12 weeks). The C min of total etravirine was 78 to 125% higher during pregnancy compared with postpartum (6 to 12 weeks), while two subjects had C min < 10 ng/mL in the postpartum period (6 to 12 weeks) [C min of total etravirine was 11% to 16% higher when these 2 subjects are excluded] (see Table 7) [see Use in Specific Populations (8.1) ] . Increased etravirine exposures during pregnancy are not considered clinically significant. The protein binding of etravirine was similar (> 99%) during the second trimester, third trimester, and postpartum period. Table 7: Pharmacokinetic Results of Total Etravirine After Administration of Etravirine 200 mg Twice Daily as Part of an Antiretroviral Regimen, During the 2 nd Trimester of Pregnancy, the 3 rd Trimester of Pregnancy, and Postpartum. Parameter Mean ± SD (median) Postpartum N=10 2 nd Trimester N=13 3 rd Trimester N=10* C min , ng/mL 269 ± 182 (284) † 383 ± 210 (346) 349 ± 103 (371) C max , ng/mL 569 ± 261 (528) 774 ± 300 (828) 785 ± 238 (694) AUC 12h , ng•h/mL 5,004 ± 2521 (5,246) 6,617 ± 2766 (6,836) 6,846 ± 1482 (6,028) *n=9 for AUC 12h † Two subjects had C min <10 ng/mL, C min was 334 ± 135 (315) in the postpartum period when these subjects were excluded from the descriptive analysis (N=8). Patients with Hepatitis B and/or Hepatitis C Virus Co-Infection Population pharmacokinetic analysis of the TMC125-C206 and TMC125-C216 trials showed reduced clearance for etravirine in HIV-1-infected subjects with hepatitis B and/or C virus co-infection. Based upon the safety profile of etravirine [see Adverse Reactions (6) ] , no dose adjustment is necessary in patients co-infected with hepatitis B and/or C virus. Drug Interactions Etravirine is a substrate of CYP3A, CYP2C9, and CYP2C19. Therefore, co-administration of etravirine with drugs that induce or inhibit CYP3A, CYP2C9, and CYP2C19 may alter the therapeutic effect or adverse reaction profile of etravirine. Etravirine is an inducer of CYP3A and inhibitor of CYP2C9, CYP2C19 and P-gp. Therefore, co-administration of drugs that are substrates of CYP3A, CYP2C9 and CYP2C19 or are transported by P-gp with etravirine may alter the therapeutic effect or adverse reaction profile of the co-administered drug(s). Drug interaction studies were performed with etravirine and other drugs likely to be co-administered and some drugs commonly used as probes for pharmacokinetic interactions. The effects of co-administration of other drugs on the AUC, C max , and C min values of etravirine are summarized in Table 8 (effect of other drugs on etravirine). The effect of co-administration of etravirine on the AUC, C max , and C min values of other drugs are summarized in Table 9 (effect of etravirine on other drugs). For information regarding clinical recommendations, [see Drug Interactions (7) ] . Table 8: Drug Interactions: Pharmacokinetic Parameters for Etravirine in the Presence of Co-administered Drugs Co-administered Drug Dose/Schedule of Co-administered Drug N Exposure Mean Ratio of Etravirine Pharmacokinetic Parameters 90% CI; No Effect = 1.00 C max AUC C min Co-administration with HIV protease inhibitors (PIs) Atazanavir 400 mg once daily 14 ↑ 1.47 (1.36 to 1.59) 1.50 (1.41 to 1.59) 1.58 (1.46 to 1.70) Atazanavir/ritonavir* 300 mg/100 mg once daily 14 ↑ 1.30 (1.17 to 1.44) 1.30 (1.18 to 1.44) 1.26 (1.12 to 1.42) Darunavir/ritonavir 600 mg/100 mg twice daily 14 ↓ 0.68 (0.57 to 0.82) 0.63 (0.54 to 0.73) 0.51 (0.44 to 0.61) Lopinavir/ritonavir (tablet) 400 mg/100 mg twice daily 16 ↓ 0.70 (0.64 to 0.78) 0.65 (0.59 to 0.71) 0.55 (0.49 to 0.62) Ritonavir 600 mg twice daily 11 ↓ 0.68 (0.55 to 0.85) 0.54 (0.41 to 0.73) N.A. Saquinavir/ritonavir 1,000 mg/100 mg twice daily 14 ↓ 0.63 (0.53 to 0.75) 0.67 (0.56 to 0.80) 0.71 (0.58 to 0.87) Tipranavir/ritonavir 500 mg/200 mg twice daily 19 ↓ 0.29 (0.22 to 0.40) 0.24 (0.18 to 0.33) 0.18 (0.13 to 0.25) Co-administration with nucleoside reverse transcriptase inhibitors (NRTIs) Didanosine 400 mg once daily 15 ↔ 1.16 (1.02 to 1.32) 1.11 (0.99 to 1.25) 1.05 (0.93 to 1.18) Tenofovir disoproxil fumarate 300 mg once daily 23 ↓ 0.81 (0.75 to 0.88) 0.81 (0.75 to 0.88) 0.82 (0.73 to 0.91) Co-administration with CCR5 antagonists Maraviroc 300 mg twice daily 14 ↔ 1.05 (0.95 to 1.17) 1.06 (0.99 to 1.14) 1.08 (0.98 to 1.19) Maraviroc (when co-administered with darunavir/ritonavir) † 150 mg/600 mg/100 mg twice daily 10 ↔ 1.08 (0.98 to 1.20) 1.00 (0.86 to 1.15) 0.81 (0.65 to 1.01) Co-administration with integrase strand transfer inhibitors Raltegravir 400 mg twice daily 19 ↔ 1.04 (0.97 to 1.12) 1.10 (1.03 to 1.16) 1.17 (1.10 to 1.26) Co-administration with other drugs Artemether/lumefantrine 80 mg/480 mg, 6 doses at 0, 8, 24, 36, 48, and 60 hours 14 ↔ 1.11 (1.06 to 1.17) 1.10 (1.06 to 1.15) 1.08 (1.04 to 1.14) Atorvastatin 40 mg once daily 16 ↔ 0.97 (0.93 to 1.02) 1.02 (0.97 to 1.07) 1.10 (1.02 to 1.19) Clarithromycin 500 mg twice daily 15 ↑ 1.46 (1.38 to 1.56) 1.42 (1.34 to 1.50) 1.46 (1.36 to 1.58) Fluconazole 200 mg once daily in the morning 16 ↑ 1.75 (1.60 to 1.91) 1.86 (1.73 to 2.00) 2.09 (1.90 to 2.31) Omeprazole 40 mg once daily 18 ↑ 1.17 (0.96 to 1.43) 1.41 (1.22 to 1.62) N.A. Paroxetine 20 mg once daily 16 ↔ 1.05 (0.96 to 1.15) 1.01 (0.93 to 1.10) 1.07 (0.98 to 1.17) Ranitidine 150 mg twice daily 18 ↓ 0.94 (0.75 to 1.17) 0.86 (0.76 to 0.97) N.A. Rifabutin 300 mg once daily 12 ↓ 0.63 (0.53 to 0.74) 0.63 (0.54 to 0.74) 0.65 (0.56 to 0.74) Voriconazole 200 mg twice daily 16 ↑ 1.26 (1.16 to 1.38) 1.36 (1.25 to 1.47) 1.52 (1.41 to 1.64) CI = Confidence Interval; N = number of subjects with data; N.A. = not available; ↑ = increase; ↓ = decrease; ↔ = no change * The systemic exposure of etravirine when co-administered with atazanavir/ritonavir in HIV infected subjects is similar to exposures of etravirine observed in the Phase 3 trials after co-administration of etravirine and darunavir/ritonavir (as part of the background regimen). † The reference for etravirine exposure is the pharmacokinetic parameters of etravirine in the presence of darunavir/ritonavir. Table 9: Drug Interactions: Pharmacokinetic Parameters for Co-administered Drugs in the Presence of Etravirine Co-administered Drug Dose/Schedule of Co-administered Drug N Exposure Mean Ratio of Co-administered Drug Pharmacokinetic Parameters 90% CI; No effect = 1.00 C max AUC C min Co-administration with HIV protease inhibitors (PIs) Atazanavir 400 mg once daily 14 ↓ 0.97 (0.73 to 1.29) 0.83 (0.63 to 1.09) 0.53 (0.38 to 0.73) Atazanavir/ritonavir 300 mg/100 mg once daily 13 ↓ 0.97 (0.89 to 1.05) 0.86 (0.79 to 0.93) 0.62 (0.55 to 0.71) Atazanavir/ritonavir* 300 mg/100 mg once daily 20 ↓ 0.96 (0.80 to 1.16) 0.96 (0.76 to 1.22) 0.82 (0.55 to 1.22) Darunavir/ritonavir 600 mg/100 mg twice daily 15 ↔ 1.11 (1.01 to 1.22) 1.15 (1.05 to 1.26) 1.02 (0.90 to 1.17) Fosamprenavir/ritonavir 700 mg/100 mg twice daily 8 ↑ 1.62 (1.47 to 1.79) 1.69 (1.53 to 1.86) 1.77 (1.39 to 2.25) Lopinavir/ritonavir (tablet) 400 mg/100 mg twice daily 16 ↔ 0.89 (0.82 to 0.96) 0.87 (0.83 to 0.92) 0.80 (0.73 to 0.88) Saquinavir/ritonavir 1,000 mg/100 mg twice daily 15 ↔ 1.00 (0.70 to 1.42) 0.95 (0.64 to 1.42) 0.80 (0.46 to 1.38) Tipranavir/ritonavir 500 mg/200 mg twice daily 19 ↑ 1.14 (1.02 to 1.27) 1.18 (1.03 to 1.36) 1.24 (0.96 to 1.59) Co-administration with nucleoside reverse transcriptase inhibitors (NRTIs) Didanosine 400 mg once daily 14 ↔ 0.91 (0.58 to 1.42) 0.99 (0.79 to 1.25) N.A. Tenofovir disoproxil fumarate 300 mg once daily 19 ↔ 1.15 (1.04 to 1.27) 1.15 (1.09 to 1.21) 1.19 (1.13 to 1.26) Co-administration with CCR5 antagonists Maraviroc 300 mg twice daily 14 ↓ 0.40 (0.28 to 0.57) 0.47 (0.38 to 0.58) 0.61 (0.53 to 0.71) Maraviroc (when co-administered with darunavir/ritonavir) † 150 mg/600 mg/100 mg twice daily 10 ↑ 1.77 (1.20 to 2.60) 3.10 (2.57 to 3.74) 5.27 (4.51 to 6.15) Co-administration with integrase strand transfer inhibitors Dolutegravir 50 mg once daily 16 ↓ 0.48 (0.43 to 0.54) 0.29 (0.26 to 0.34) 0.12 (0.09 to 0.16) Dolutegravir (when co-administered with darunavir/ritonavir) 50 mg once daily + 600/100 mg twice daily 9 ↓ 0.88 (0.78 to 1.00) 0.75 (0.69 to 0.81) 0.63 (0.52 to 0.76) Dolutegravir (when co-administered with lopinavir/ritonavir 50 mg once daily + 400/100 mg twice daily 8 ↔ 1.07 (1.02 to 1.13) 1.11 (1.02 to 1.20) 1.28 (1.13 to 1.45) Raltegravir 400 mg twice daily 19 ↓ 0.89 (0.68 to 1.15) 0.90 (0.68 to 1.18) 0.66 (0.34 to 1.26) Co-administration with other drugs Artemether 80 mg/480 mg, 6 doses at 0, 8, 24, 36, 48, and 60 hours 15 ↓ 0.72 (0.55 to 0.94) 0.62 (0.48 to 0.80) 0.82 (0.67 to 1.01) Dihydroartemisinin 15 ↓ 0.84 (0.71 to 0.99) 0.85 (0.75 to 0.97) 0.83 (0.71 to 0.97) Lumefantrine 15 ↓ 1.07 (0.94 to 1.23) 0.87 (0.77 to 0.98) 0.97 (0.83 to 1.15) Atorvastatin 40 mg once daily 16 ↓ 1.04 (0.84 to 1.30) 0.63 (0.58 to 0.68) N.A. 2-hydroxy-atorvastatin 16 ↑ 1.76 (1.60 to 1.94) 1.27 (1.19 to 1.36) N.A. Buprenorphine Individual dose regimen ranging from 4/1 mg to 16/4 mg once daily 16 ↓ 0.89 (0.76 to 1.05) 0.75 (0.66 to 0.84) 0.60 (0.52 to 0.68) Norbuprenorphine 16 ↔ 1.08 (0.95 to 1.23) 0.88 (0.81 to 0.96) 0.76 (0.67 to 0.87) Clarithromycin 500 mg twice daily 15 ↓ 0.66 (0.57 to 0.77) 0.61 (0.53 to 0.69) 0.47 (0.38 to 0.57) 14-hydroxy-clarithromycin 15 ↑ 1.33 (1.13 to 1.56) 1.21 (1.05 to 1.39) 1.05 (0.90 to 1.22) Digoxin 0.5 mg single-dose 16 ↑ 1.19 (0.96 to 1.49) 1.18 (0.90 to 1.56) N.A. Ethinylestradiol 0.035 mg once daily 16 ↑ 1.33 (1.21 to 1.46) 1.22 (1.13 to 1.31) 1.09 (1.01 to 1.18) Norethindrone 1 mg once daily 16 ↔ 1.05 (0.98 to 1.12) 0.95 (0.90 to 0.99) 0.78 (0.68 to 0.90) Fluconazole 200 mg once daily in the morning 15 ↔ 0.92 (0.85 to 1.00) 0.94 (0.88 to 1.01) 0.91 (0.84 to 0.98) R(-) Methadone Individual dose regimen ranging from 60 to 130 mg/day 16 ↔ 1.02 (0.96 to 1.09) 1.06 (0.99 to 1.13) 1.10 (1.02 to 1.19) S(+) Methadone 16 ↔ 0.89 (0.83 to 0.97) 0.89 (0.82 to 0.96) 0.89 (0.81 to 0.98) Paroxetine 20 mg once daily 16 ↔ 1.06 (0.95 to 1.20) 1.03 (0.90 to 1.18) 0.87 (0.75 to 1.02) Rifabutin 300 mg once daily 12 ↓ 0.90 (0.78 to 1.03) 0.83 (0.75 to 0.94) 0.76 (0.66 to 0.87) 25- O -desacetylrifabutin 300 mg once daily 12 ↓ 0.85 (0.72 to 1.00) 0.83 (0.74 to 0.92) 0.78 (0.70 to 0.87) Sildenafil 50 mg single-dose 15 ↓ 0.55 (0.40 to 0.75) 0.43 (0.36 to 0.51) N.A. N-desmethyl-sildenafil 15 ↓ 0.75 (0.59 to 0.96) 0.59 (0.52 to 0.68) N.A. Voriconazole 200 mg twice daily 14 ↑ 0.95 (0.75 to 1.21) 1.14 (0.88 to 1.47) 1.23 (0.87 to 1.75) CI = Confidence Interval; N = number of subjects with data; N.A. = not available; ↑ = increase; ↓ = decrease; ↔ = no change * HIV-infected subjects † compared to maraviroc 150 mg twice daily 12.4 Microbiology Mechanism of Action Etravirine is an NNRTI of HIV-1. Etravirine binds directly to reverse transcriptase (RT) and blocks the RNA-dependent and DNA-dependent DNA polymerase activities by causing a disruption of the enzyme's catalytic site. Etravirine does not inhibit the human DNA polymerases α, β, and γ. Antiviral Activity in Cell Culture Etravirine exhibited activity against laboratory strains and clinical isolates of wild-type HIV-1 in acutely infected T-cell lines, human peripheral blood mononuclear cells, and human monocytes/macrophages with median EC 50 values ranging from 0.9 nM to 5.5 nM (i.e. 0.4 ng/mL to 2.4 ng/mL). Etravirine demonstrated antiviral activity in cell culture against a broad panel of HIV-1 group M isolates (subtype A, B, C, D, E, F, G) with EC 50 values ranging from 0.29 nM to 1.65 nM and EC 50 values ranging from 11.5 nM to 21.7 nM against group O primary isolates. Etravirine did not show antagonism when studied in combination with the following antiretroviral drugs—the NNRTIs delavirdine, efavirenz, and nevirapine; the N(t)RTIs abacavir, didanosine, emtricitabine, lamivudine, stavudine, tenofovir, and zidovudine; the PIs amprenavir, atazanavir, darunavir, indinavir, lopinavir, nelfinavir, ritonavir, saquinavir, and tipranavir; the gp41 fusion inhibitor ENF; the integrase strand transfer inhibitor raltegravir and the CCR5 co-receptor antagonist maraviroc. Resistance In Cell Culture Etravirine-resistant strains were selected in cell culture originating from wild-type HIV-1 of different origins and subtypes, as well as NNRTI resistant HIV-1. Development of reduced susceptibility to etravirine typically required more than one substitution in reverse transcriptase of which the following were observed most frequently: L100I, E138K, E138G, V179I, Y181C, and M230I. In Treatment-Experienced Subjects In the Phase 3 trials TMC125-C206 and TMC125-C216, substitutions that developed most commonly in subjects with virologic failure at Week 48 to the etravirine-containing regimen were V179F, V179I, and Y181C which usually emerged in a background of multiple other NNRTI resistance-associated substitutions. In all the trials conducted with etravirine in HIV-1 infected subjects, the following substitutions emerged most commonly: L100I, E138G, V179F, V179I, Y181C and H221Y. Other NNRTI-resistance-associated substitutions which emerged on etravirine treatment in less than 10% of the virologic failure isolates included K101E/H/P, K103N/R, V106I/M, V108I, Y181I, Y188L, V189I, G190S/C, N348I and R356K. The emergence of NNRTI substitutions on etravirine treatment contributed to decreased susceptibility to etravirine with a median fold-change in etravirine susceptibility of 40-fold from reference and a median fold-change of 6-fold from baseline. Cross-Resistance Cross-resistance among NNRTIs has been observed. Cross-resistance to delavirdine, efavirenz, and/or nevirapine is expected after virologic failure with an etravirine-containing regimen. Virologic failure on a rilpivirine-containing regimen with development of rilpivirine resistance is likely to result in cross-resistance to etravirine (see Treatment-Naïve HIV-1-Infected Subjects in the Phase 3 Trials for EDURANT (rilpivirine) below). Cross-resistance to etravirine has been observed after virologic failure on a doravirine-containing regimen with development of doravirine resistance. Some NNRTI-resistant viruses are susceptible to etravirine, but genotypic and phenotypic testing should guide the use of etravirine (see Baseline Genotype/Phenotype and Virologic Outcome Analyses below). Site-Directed NNRTI Mutant Virus Etravirine showed antiviral activity against 55 of 65 HIV-1 strains (85%) with single amino acid substitutions at RT positions associated with NNRTI resistance, including the most commonly found K103N. The single amino acid substitutions associated with an etravirine reduction in susceptibility greater than 3-fold were K101A, K101P, K101Q, E138G, E138Q, Y181C, Y181I, Y181T, Y181V, and M230L, and of these, the greatest reductions were Y181I (13-fold change in EC 50 value) and Y181V (17-fold change in EC 50 value). Mutant strains containing a single NNRTI resistance-associated substitution (K101P, K101Q, E138Q, or M230L) had cross-resistance between etravirine and efavirenz. The majority (39 of 61; 64%) of the NNRTI mutant viruses with 2 or 3 amino acid substitutions associated with NNRTI resistance had decreased susceptibility to etravirine (fold-change greater than 3). The highest levels of resistance to etravirine were observed for HIV-1 harboring a combination of substitutions V179F + Y181C (187 fold-change), V179F + Y181I (123 fold-change), or V179F + Y181C + F227C (888 fold-change). Clinical Isolates Etravirine retained a fold-change less than or equal to 3 against 60% of 6171 NNRTI-resistant clinical isolates. In the same panel, the proportion of clinical isolates resistant to delavirdine, efavirenz and/or nevirapine (defined as a fold-change above their respective biological cutoff values in the assay) was 79%, 87%, and 95%, respectively. In TMC125-C206 and TMC125-C216, 34% of the baseline isolates had decreased susceptibility to etravirine (fold-change greater than 3) and 60%, 69%, and 78% of all baseline isolates were resistant to delavirdine, efavirenz, and nevirapine, respectively. Of subjects who received etravirine and were virologic failures in TMC125-C206 and TMC125-C216, 90%, 84%, and 96% of viral isolates obtained at the time of treatment failure were resistant to delavirdine, efavirenz, and nevirapine, respectively. Treatment-Naïve HIV-1-Infected Subjects in the Phase 3 Trials for EDURANT (Rilpivirine) There are currently no clinical data available on the use of etravirine in subjects who experienced virologic failure on a rilpivirine-containing regimen. However, in the rilpivirine adult clinical development program, there was evidence of phenotypic cross-resistance between rilpivirine and etravirine. In the pooled analyses of the Phase 3 clinical trials for rilpivirine, 38 rilpivirine virologic failure subjects had evidence of HIV-1 strains with genotypic and phenotypic resistance to rilpivirine. Of these subjects, 89% (34 subjects) of virologic failure isolates were cross-resistant to etravirine based on phenotype data. Consequently, it can be inferred that cross-resistance to etravirine is likely after virologic failure and development of rilpivirine resistance. Refer to the prescribing information for EDURANT (rilpivirine) for further information. Baseline Genotype/Phenotype and Virologic Outcome Analyses In TMC125-C206 and TMC125-C216, the presence at baseline of the substitutions L100I, E138A, I167V, V179D, V179F, Y181I, Y181V, or G190S was associated with a decreased virologic response to etravirine. Additional substitutions associated with a decreased virologic response to etravirine when in the presence of 3 or more additional 2008 IAS-USA defined NNRTI substitutions include A98G, K101H, K103R, V106I, V179T, and Y181C. The presence of K103N, which was the most prevalent NNRTI substitution in TMC125-C206 and TMC125-C216 at baseline, did not affect the response in the etravirine arm. Overall, response rates to etravirine decreased as the number of baseline NNRTI substitutions increased (shown as the proportion of subjects achieving viral load less than 50 plasma HIV RNA copies/mL at Week 48) (Table 10). Table 10: Proportion of Subjects With Less Than 50 HIV-1 RNA Copies/mL at Week 48 by Baseline Number of IAS-USA-Defined NNRTI Substitutions* in the Non-VF Excluded Population of the Pooled TMC125-C206 and TMC125-C216 # IAS-USA-Defined NNRTI substitutions* Etravirine N=561 Re-used/not used ENF de novo ENF All ranges 61% (254/418) 76% (109/143) 0 68% (52/76) 95% (20/21) 1 67% (72/107) 77% (24/31) 2 64% (75/118) 86% (38/44) 3 55% (36/65) 62% (16/26) ≥ 4 37% (19/52) 52% (11/21) Placebo N=592 All ranges 34% (147/435) 59% (93/157) ENF: enfuvirtide * 2008 IAS-USA defined substitutions = V90I, A98G, L100I, K101E/H/P, K103N, V106A/I/M, V108I, E138A, V179D/F/T, Y181C/I/V, Y188C/H/L, G190A/S, P225H, M230L Response rates assessed by baseline etravirine phenotype are shown in Table 11. These baseline phenotype groups are based on the select subject populations in TMC125-C206 and TMC125-C216 and are not meant to represent definitive clinical susceptibility breakpoints for etravirine. The data are provided to give clinicians information on the likelihood of virologic success based on pre-treatment susceptibility to etravirine in treatment-experienced patients. Table 11: Proportion of Subjects With Less Than 50 HIV-1 RNA Copies/mL at Week 48 by Baseline Phenotype and ENF Use in the Pooled TMC125-C206 and TMC125-C216* Fold Change Etravirine N=559 Re-used/not used ENF de novo ENF Clinical response range All ranges 61% (253/416) 76% (109/143) Overall Response 0 to 3 69% (188/274) 83% (75/90) Higher than Overall Response > 3 to 13 50% (39/78) 66% (25/38) Lower than Overall Response > 13 41% (26/64) 60% (9/15) Lower than Overall Response Placebo N=583 All ranges 34% (145/429) 60% (92/154) ENF: enfuvirtide * Non-VF excluded analysis The proportion of virologic responders (viral load less than 50 HIV-1 RNA copies/mL) by the phenotypic susceptibility score (PSS) of the background therapy, including ENF, is shown in Table 12. Table 12: Virologic Response (Viral Load Less Than 50 HIV-1 RNA Copies/mL) at Week 48 by Phenotypic Susceptibility Score (PSS) in the Non-VF Excluded Population of TMC125-C206 and TMC125-C216 PSS * Etravirine + BR N=559 Placebo + BR N=586 0 43% (40/93) 5% (5/95) 1 61% (125/206) 28% (64/226) 2 77% (114/149) 59% (97/165) ≥ 3 75% (83/111) 72% (72/100) * The phenotypic susceptibility score (PSS) was defined as the total number of active antiretroviral drugs in the background therapy to which a subject’s baseline viral isolate showed sensitivity in phenotypic resistance tests. Each drug in the background therapy was scored as a ‘1’ or ‘0’ based on whether the viral isolate was considered susceptible or resistant to that drug, respectively. In the calculation of the PSS, darunavir was counted as a sensitive antiretroviral if the FC was less than or equal to 10; ENF was counted as a sensitive antiretroviral if it had not been used previously. Etravirine was not included in this calculation.

12.1 Mechanism of Action Etravirine is an antiretroviral drug [see Microbiology (12.4) ] .

12.2 Pharmacodynamics Cardiac Electrophysiology In a thorough QT/QTc study in 41 healthy subjects, etravirine 200 mg twice daily or 400 mg once daily did not affect the QT/QTc interval.

12.3 Pharmacokinetics The pharmacokinetic properties of etravirine were determined in healthy adult subjects and in treatment-experienced HIV-1-infected adult and pediatric subjects. The systemic exposures (AUC) to etravirine were lower in HIV-1-infected subjects (Table 5) than in healthy subjects. Table 5: Population Pharmacokinetic Estimates of Etravirine 200 mg Twice Daily in HIV-1-Infected Adult Subjects (Integrated Data from Phase 3 Trials at Week 48) * Parameter Etravirine N=575 AUC 12h (ng•h/mL) Geometric mean ± standard deviation 4,522 ± 4,710 Median (range) 4,380 (458 to 59,084) C 0h (ng/mL) Geometric mean ± standard deviation 297 ± 391 Median (range) 298 (2 to 4,852) * All HIV-1-infected subjects enrolled in Phase 3 clinical trials received darunavir/ritonavir 600/100 mg twice daily as part of their background regimen. Therefore, the pharmacokinetic parameter estimates shown in Table 5 account for reductions in the pharmacokinetic parameters of etravirine due to co-administration of etravirine with darunavir/ritonavir. Note: The median protein binding adjusted EC 50 for MT4 cells infected with HIV-1/IIIB in vitro equals 4 ng/mL. Absorption and Bioavailability Following oral administration, etravirine was absorbed with a T max of about 2.5 to 4 hours. The absolute oral bioavailability of etravirine is unknown. In healthy subjects, the absorption of etravirine is not affected by co-administration of oral ranitidine or omeprazole, drugs that increase gastric pH. Effects of Food on Oral Absorption The systemic exposure (AUC) to etravirine was decreased by about 50% when etravirine tablet was administered under fasting conditions, as compared to when etravirine tablet was administered following a meal. Within the range of meals studied, the systemic exposures to etravirine were similar. The total caloric content of the various meals evaluated ranged from 345 kilocalories (17 grams fat) to 1,160 kilocalories (70 grams fat). Distribution Etravirine is about 99.9% bound to plasma proteins, primarily to albumin (99.6%) and alpha 1-acid glycoprotein (97.66% to 99.02%) in vitro . The distribution of etravirine into compartments other than plasma (e.g., cerebrospinal fluid, genital tract secretions) has not been evaluated in humans. Metabolism In vitro experiments with human liver microsomes (HLMs) indicate that etravirine primarily undergoes metabolism by CYP3A, CYP2C9, and CYP2C19 enzymes. The major metabolites, formed by methyl hydroxylation of the dimethylbenzonitrile moiety, were at least 90% less active than etravirine against wild-type HIV in cell culture. Elimination After single dose oral administration of 800 mg 14 C-etravirine, 93.7% and 1.2% of the administered dose of 14 C-etravirine was recovered in the feces and urine, respectively. Unchanged etravirine accounted for 81.2% to 86.4% of the administered dose in feces. Unchanged etravirine was not detected in urine. The mean (± standard deviation) terminal elimination half-life of etravirine was about 41 (± 20) hours. Specific Populations Geriatric Patients Population pharmacokinetic analysis in HIV-infected subjects showed that etravirine pharmacokinetics are not considerably different within the age range (18 to 77 years) evaluated [see Use in Specific Populations (8.5) ] . Pediatric Patients The pharmacokinetics of etravirine in 101 treatment-experienced HIV-1-infected pediatric subjects, 6 years to less than 18 years of age showed that the administered weight-based dosages resulted in etravirine exposure comparable to that in adults receiving etravirine 200 mg twice daily [see Dosage and Administration (2.3) ] . The pharmacokinetic parameters for etravirine (AUC 12h and C 0h ) are summarized in Table 6. Table 6: Pharmacokinetic Parameters for Etravirine in Treatment-Experienced HIV-1-Infected Pediatric Subjects 6 Years to Less Than 18 Years of Age (TMC125-C213 [Population PK]) Study TMC125-C213 Age Range (years) (6 years to less than 18 years) Parameter N=101 AUC 12h (ng•h/mL) Geometric mean ± standard deviation 3,742 ± 4,314 Median (range) 4,499 (62 to 28,865) C 0h (ng/mL) Geometric mean ± standard deviation 205 ± 342 Median (range) 287 (2 to 2,276) The pharmacokinetics and dose of etravirine in pediatric subjects less than 2 years of age have not been established [see Use in Specific Populations (8.4) ]. Additional pediatric use information is approved for Janssen Products, LP’s INTELENCE ® (etravirine) tablets. However, due to Janssen Products, LP’s marketing exclusivity rights, this drug product is not labeled with that pediatric information. Male and Female Patients No significant pharmacokinetic differences have been observed between males and females. Racial or Ethnic Groups Population pharmacokinetic analysis of etravirine in HIV-infected subjects did not show an effect of race on exposure to etravirine. Patients with Renal Impairment The pharmacokinetics of etravirine have not been studied in patients with renal impairment. The results from a mass balance study with 14 C-etravirine showed that less than 1.2% of the administered dose of etravirine is excreted in the urine as metabolites. No unchanged drug was detected in the urine. As etravirine is highly bound to plasma proteins, it is unlikely that it will be significantly removed by hemodialysis or peritoneal dialysis [see Use in Specific Populations (8.7) ] . Patients with Hepatic Impairment Etravirine is primarily metabolized by the liver. The steady-state pharmacokinetic parameters of etravirine were similar after multiple dose administration of etravirine to subjects with normal hepatic function (16 subjects), mild hepatic impairment (Child-Pugh Class A, 8 subjects), and moderate hepatic impairment (Child-Pugh Class B, 8 subjects). The effect of severe hepatic impairment on the pharmacokinetics of etravirine has not been evaluated [see Use in Specific Populations (8.6) ] . Pregnancy and Postpartum After intake of etravirine 200 mg twice daily in combination with other antiretroviral agents (13 subjects with 2 NRTIs, 1 subject with 2 NRTIs + lopinavir + ritonavir, 1 subject with 2 NRTIs + raltegravir), based on intra-individual comparison, the C max and AUC 12h of total etravirine were 23% to 42% higher during pregnancy compared with postpartum (6 to 12 weeks). The C min of total etravirine was 78 to 125% higher during pregnancy compared with postpartum (6 to 12 weeks), while two subjects had C min < 10 ng/mL in the postpartum period (6 to 12 weeks) [C min of total etravirine was 11% to 16% higher when these 2 subjects are excluded] (see Table 7) [see Use in Specific Populations (8.1) ] . Increased etravirine exposures during pregnancy are not considered clinically significant. The protein binding of etravirine was similar (> 99%) during the second trimester, third trimester, and postpartum period. Table 7: Pharmacokinetic Results of Total Etravirine After Administration of Etravirine 200 mg Twice Daily as Part of an Antiretroviral Regimen, During the 2 nd Trimester of Pregnancy, the 3 rd Trimester of Pregnancy, and Postpartum. Parameter Mean ± SD (median) Postpartum N=10 2 nd Trimester N=13 3 rd Trimester N=10* C min , ng/mL 269 ± 182 (284) † 383 ± 210 (346) 349 ± 103 (371) C max , ng/mL 569 ± 261 (528) 774 ± 300 (828) 785 ± 238 (694) AUC 12h , ng•h/mL 5,004 ± 2521 (5,246) 6,617 ± 2766 (6,836) 6,846 ± 1482 (6,028) *n=9 for AUC 12h † Two subjects had C min <10 ng/mL, C min was 334 ± 135 (315) in the postpartum period when these subjects were excluded from the descriptive analysis (N=8). Patients with Hepatitis B and/or Hepatitis C Virus Co-Infection Population pharmacokinetic analysis of the TMC125-C206 and TMC125-C216 trials showed reduced clearance for etravirine in HIV-1-infected subjects with hepatitis B and/or C virus co-infection. Based upon the safety profile of etravirine [see Adverse Reactions (6) ] , no dose adjustment is necessary in patients co-infected with hepatitis B and/or C virus. Drug Interactions Etravirine is a substrate of CYP3A, CYP2C9, and CYP2C19. Therefore, co-administration of etravirine with drugs that induce or inhibit CYP3A, CYP2C9, and CYP2C19 may alter the therapeutic effect or adverse reaction profile of etravirine. Etravirine is an inducer of CYP3A and inhibitor of CYP2C9, CYP2C19 and P-gp. Therefore, co-administration of drugs that are substrates of CYP3A, CYP2C9 and CYP2C19 or are transported by P-gp with etravirine may alter the therapeutic effect or adverse reaction profile of the co-administered drug(s). Drug interaction studies were performed with etravirine and other drugs likely to be co-administered and some drugs commonly used as probes for pharmacokinetic interactions. The effects of co-administration of other drugs on the AUC, C max , and C min values of etravirine are summarized in Table 8 (effect of other drugs on etravirine). The effect of co-administration of etravirine on the AUC, C max , and C min values of other drugs are summarized in Table 9 (effect of etravirine on other drugs). For information regarding clinical recommendations, [see Drug Interactions (7) ] . Table 8: Drug Interactions: Pharmacokinetic Parameters for Etravirine in the Presence of Co-administered Drugs Co-administered Drug Dose/Schedule of Co-administered Drug N Exposure Mean Ratio of Etravirine Pharmacokinetic Parameters 90% CI; No Effect = 1.00 C max AUC C min Co-administration with HIV protease inhibitors (PIs) Atazanavir 400 mg once daily 14 ↑ 1.47 (1.36 to 1.59) 1.50 (1.41 to 1.59) 1.58 (1.46 to 1.70) Atazanavir/ritonavir* 300 mg/100 mg once daily 14 ↑ 1.30 (1.17 to 1.44) 1.30 (1.18 to 1.44) 1.26 (1.12 to 1.42) Darunavir/ritonavir 600 mg/100 mg twice daily 14 ↓ 0.68 (0.57 to 0.82) 0.63 (0.54 to 0.73) 0.51 (0.44 to 0.61) Lopinavir/ritonavir (tablet) 400 mg/100 mg twice daily 16 ↓ 0.70 (0.64 to 0.78) 0.65 (0.59 to 0.71) 0.55 (0.49 to 0.62) Ritonavir 600 mg twice daily 11 ↓ 0.68 (0.55 to 0.85) 0.54 (0.41 to 0.73) N.A. Saquinavir/ritonavir 1,000 mg/100 mg twice daily 14 ↓ 0.63 (0.53 to 0.75) 0.67 (0.56 to 0.80) 0.71 (0.58 to 0.87) Tipranavir/ritonavir 500 mg/200 mg twice daily 19 ↓ 0.29 (0.22 to 0.40) 0.24 (0.18 to 0.33) 0.18 (0.13 to 0.25) Co-administration with nucleoside reverse transcriptase inhibitors (NRTIs) Didanosine 400 mg once daily 15 ↔ 1.16 (1.02 to 1.32) 1.11 (0.99 to 1.25) 1.05 (0.93 to 1.18) Tenofovir disoproxil fumarate 300 mg once daily 23 ↓ 0.81 (0.75 to 0.88) 0.81 (0.75 to 0.88) 0.82 (0.73 to 0.91) Co-administration with CCR5 antagonists Maraviroc 300 mg twice daily 14 ↔ 1.05 (0.95 to 1.17) 1.06 (0.99 to 1.14) 1.08 (0.98 to 1.19) Maraviroc (when co-administered with darunavir/ritonavir) † 150 mg/600 mg/100 mg twice daily 10 ↔ 1.08 (0.98 to 1.20) 1.00 (0.86 to 1.15) 0.81 (0.65 to 1.01) Co-administration with integrase strand transfer inhibitors Raltegravir 400 mg twice daily 19 ↔ 1.04 (0.97 to 1.12) 1.10 (1.03 to 1.16) 1.17 (1.10 to 1.26) Co-administration with other drugs Artemether/lumefantrine 80 mg/480 mg, 6 doses at 0, 8, 24, 36, 48, and 60 hours 14 ↔ 1.11 (1.06 to 1.17) 1.10 (1.06 to 1.15) 1.08 (1.04 to 1.14) Atorvastatin 40 mg once daily 16 ↔ 0.97 (0.93 to 1.02) 1.02 (0.97 to 1.07) 1.10 (1.02 to 1.19) Clarithromycin 500 mg twice daily 15 ↑ 1.46 (1.38 to 1.56) 1.42 (1.34 to 1.50) 1.46 (1.36 to 1.58) Fluconazole 200 mg once daily in the morning 16 ↑ 1.75 (1.60 to 1.91) 1.86 (1.73 to 2.00) 2.09 (1.90 to 2.31) Omeprazole 40 mg once daily 18 ↑ 1.17 (0.96 to 1.43) 1.41 (1.22 to 1.62) N.A. Paroxetine 20 mg once daily 16 ↔ 1.05 (0.96 to 1.15) 1.01 (0.93 to 1.10) 1.07 (0.98 to 1.17) Ranitidine 150 mg twice daily 18 ↓ 0.94 (0.75 to 1.17) 0.86 (0.76 to 0.97) N.A. Rifabutin 300 mg once daily 12 ↓ 0.63 (0.53 to 0.74) 0.63 (0.54 to 0.74) 0.65 (0.56 to 0.74) Voriconazole 200 mg twice daily 16 ↑ 1.26 (1.16 to 1.38) 1.36 (1.25 to 1.47) 1.52 (1.41 to 1.64) CI = Confidence Interval; N = number of subjects with data; N.A. = not available; ↑ = increase; ↓ = decrease; ↔ = no change * The systemic exposure of etravirine when co-administered with atazanavir/ritonavir in HIV infected subjects is similar to exposures of etravirine observed in the Phase 3 trials after co-administration of etravirine and darunavir/ritonavir (as part of the background regimen). † The reference for etravirine exposure is the pharmacokinetic parameters of etravirine in the presence of darunavir/ritonavir. Table 9: Drug Interactions: Pharmacokinetic Parameters for Co-administered Drugs in the Presence of Etravirine Co-administered Drug Dose/Schedule of Co-administered Drug N Exposure Mean Ratio of Co-administered Drug Pharmacokinetic Parameters 90% CI; No effect = 1.00 C max AUC C min Co-administration with HIV protease inhibitors (PIs) Atazanavir 400 mg once daily 14 ↓ 0.97 (0.73 to 1.29) 0.83 (0.63 to 1.09) 0.53 (0.38 to 0.73) Atazanavir/ritonavir 300 mg/100 mg once daily 13 ↓ 0.97 (0.89 to 1.05) 0.86 (0.79 to 0.93) 0.62 (0.55 to 0.71) Atazanavir/ritonavir* 300 mg/100 mg once daily 20 ↓ 0.96 (0.80 to 1.16) 0.96 (0.76 to 1.22) 0.82 (0.55 to 1.22) Darunavir/ritonavir 600 mg/100 mg twice daily 15 ↔ 1.11 (1.01 to 1.22) 1.15 (1.05 to 1.26) 1.02 (0.90 to 1.17) Fosamprenavir/ritonavir 700 mg/100 mg twice daily 8 ↑ 1.62 (1.47 to 1.79) 1.69 (1.53 to 1.86) 1.77 (1.39 to 2.25) Lopinavir/ritonavir (tablet) 400 mg/100 mg twice daily 16 ↔ 0.89 (0.82 to 0.96) 0.87 (0.83 to 0.92) 0.80 (0.73 to 0.88) Saquinavir/ritonavir 1,000 mg/100 mg twice daily 15 ↔ 1.00 (0.70 to 1.42) 0.95 (0.64 to 1.42) 0.80 (0.46 to 1.38) Tipranavir/ritonavir 500 mg/200 mg twice daily 19 ↑ 1.14 (1.02 to 1.27) 1.18 (1.03 to 1.36) 1.24 (0.96 to 1.59) Co-administration with nucleoside reverse transcriptase inhibitors (NRTIs) Didanosine 400 mg once daily 14 ↔ 0.91 (0.58 to 1.42) 0.99 (0.79 to 1.25) N.A. Tenofovir disoproxil fumarate 300 mg once daily 19 ↔ 1.15 (1.04 to 1.27) 1.15 (1.09 to 1.21) 1.19 (1.13 to 1.26) Co-administration with CCR5 antagonists Maraviroc 300 mg twice daily 14 ↓ 0.40 (0.28 to 0.57) 0.47 (0.38 to 0.58) 0.61 (0.53 to 0.71) Maraviroc (when co-administered with darunavir/ritonavir) † 150 mg/600 mg/100 mg twice daily 10 ↑ 1.77 (1.20 to 2.60) 3.10 (2.57 to 3.74) 5.27 (4.51 to 6.15) Co-administration with integrase strand transfer inhibitors Dolutegravir 50 mg once daily 16 ↓ 0.48 (0.43 to 0.54) 0.29 (0.26 to 0.34) 0.12 (0.09 to 0.16) Dolutegravir (when co-administered with darunavir/ritonavir) 50 mg once daily + 600/100 mg twice daily 9 ↓ 0.88 (0.78 to 1.00) 0.75 (0.69 to 0.81) 0.63 (0.52 to 0.76) Dolutegravir (when co-administered with lopinavir/ritonavir 50 mg once daily + 400/100 mg twice daily 8 ↔ 1.07 (1.02 to 1.13) 1.11 (1.02 to 1.20) 1.28 (1.13 to 1.45) Raltegravir 400 mg twice daily 19 ↓ 0.89 (0.68 to 1.15) 0.90 (0.68 to 1.18) 0.66 (0.34 to 1.26) Co-administration with other drugs Artemether 80 mg/480 mg, 6 doses at 0, 8, 24, 36, 48, and 60 hours 15 ↓ 0.72 (0.55 to 0.94) 0.62 (0.48 to 0.80) 0.82 (0.67 to 1.01) Dihydroartemisinin 15 ↓ 0.84 (0.71 to 0.99) 0.85 (0.75 to 0.97) 0.83 (0.71 to 0.97) Lumefantrine 15 ↓ 1.07 (0.94 to 1.23) 0.87 (0.77 to 0.98) 0.97 (0.83 to 1.15) Atorvastatin 40 mg once daily 16 ↓ 1.04 (0.84 to 1.30) 0.63 (0.58 to 0.68) N.A. 2-hydroxy-atorvastatin 16 ↑ 1.76 (1.60 to 1.94) 1.27 (1.19 to 1.36) N.A. Buprenorphine Individual dose regimen ranging from 4/1 mg to 16/4 mg once daily 16 ↓ 0.89 (0.76 to 1.05) 0.75 (0.66 to 0.84) 0.60 (0.52 to 0.68) Norbuprenorphine 16 ↔ 1.08 (0.95 to 1.23) 0.88 (0.81 to 0.96) 0.76 (0.67 to 0.87) Clarithromycin 500 mg twice daily 15 ↓ 0.66 (0.57 to 0.77) 0.61 (0.53 to 0.69) 0.47 (0.38 to 0.57) 14-hydroxy-clarithromycin 15 ↑ 1.33 (1.13 to 1.56) 1.21 (1.05 to 1.39) 1.05 (0.90 to 1.22) Digoxin 0.5 mg single-dose 16 ↑ 1.19 (0.96 to 1.49) 1.18 (0.90 to 1.56) N.A. Ethinylestradiol 0.035 mg once daily 16 ↑ 1.33 (1.21 to 1.46) 1.22 (1.13 to 1.31) 1.09 (1.01 to 1.18) Norethindrone 1 mg once daily 16 ↔ 1.05 (0.98 to 1.12) 0.95 (0.90 to 0.99) 0.78 (0.68 to 0.90) Fluconazole 200 mg once daily in the morning 15 ↔ 0.92 (0.85 to 1.00) 0.94 (0.88 to 1.01) 0.91 (0.84 to 0.98) R(-) Methadone Individual dose regimen ranging from 60 to 130 mg/day 16 ↔ 1.02 (0.96 to 1.09) 1.06 (0.99 to 1.13) 1.10 (1.02 to 1.19) S(+) Methadone 16 ↔ 0.89 (0.83 to 0.97) 0.89 (0.82 to 0.96) 0.89 (0.81 to 0.98) Paroxetine 20 mg once daily 16 ↔ 1.06 (0.95 to 1.20) 1.03 (0.90 to 1.18) 0.87 (0.75 to 1.02) Rifabutin 300 mg once daily 12 ↓ 0.90 (0.78 to 1.03) 0.83 (0.75 to 0.94) 0.76 (0.66 to 0.87) 25- O -desacetylrifabutin 300 mg once daily 12 ↓ 0.85 (0.72 to 1.00) 0.83 (0.74 to 0.92) 0.78 (0.70 to 0.87) Sildenafil 50 mg single-dose 15 ↓ 0.55 (0.40 to 0.75) 0.43 (0.36 to 0.51) N.A. N-desmethyl-sildenafil 15 ↓ 0.75 (0.59 to 0.96) 0.59 (0.52 to 0.68) N.A. Voriconazole 200 mg twice daily 14 ↑ 0.95 (0.75 to 1.21) 1.14 (0.88 to 1.47) 1.23 (0.87 to 1.75) CI = Confidence Interval; N = number of subjects with data; N.A. = not available; ↑ = increase; ↓ = decrease; ↔ = no change * HIV-infected subjects † compared to maraviroc 150 mg twice daily

20230906

9

3 DOSAGE FORMS AND STRENGTHS 25 mg white to off-white, oval shaped, uncoated tablets debossed with “A56” on one side and score on the other side. 100 mg white to off-white oval shaped, uncoated tablets debossed with “AC75” on one side and plain on the other side. 200 mg white to off-white, oval shaped, uncoated tablets debossed with “AC76” on one side and plain on the other side. Tablets: 25 mg, 100 mg, and 200 mg (3)

etravirine etravirine ETRAVIRINE ETRAVIRINE CROSCARMELLOSE SODIUM CROSPOVIDONE HYPROMELLOSE 2910 (6 MPA.S) LOW-SUBSTITUTED HYDROXYPROPYL CELLULOSE, UNSPECIFIED MAGNESIUM STEARATE MICROCRYSTALLINE CELLULOSE SILICON DIOXIDE white to off-white A56 etravirine etravirine ETRAVIRINE ETRAVIRINE CROSCARMELLOSE SODIUM CROSPOVIDONE HYPROMELLOSE 2910 (6 MPA.S) LOW-SUBSTITUTED HYDROXYPROPYL CELLULOSE, UNSPECIFIED MAGNESIUM STEARATE MICROCRYSTALLINE CELLULOSE SILICON DIOXIDE white to off-white AC75 etravirine etravirine ETRAVIRINE ETRAVIRINE CROSCARMELLOSE SODIUM CROSPOVIDONE HYPROMELLOSE 2910 (6 MPA.S) LOW-SUBSTITUTED HYDROXYPROPYL CELLULOSE, UNSPECIFIED MAGNESIUM STEARATE MICROCRYSTALLINE CELLULOSE SILICON DIOXIDE white to off-white AC76

13.1 Carcinogenesis, Mutagenesis, Impairment of Fertility Carcinogenesis Etravirine was evaluated for carcinogenic potential by oral gavage administration to mice and rats for up to approximately 104 weeks. Daily doses of 50 mg/kg, 200 mg/kg and 400 mg/kg were administered to mice and doses of 70 mg/kg, 200 mg/kg and 600 mg/kg were administered to rats in the initial period of approximately 41 to 52 weeks. The high and middle doses were subsequently adjusted due to tolerability and reduced by 50% in mice and by 50% to 66% in rats to allow for completion of the studies. In the mouse study, statistically significant increases in the incidences of hepatocellular carcinoma and incidences of hepatocellular adenomas or carcinomas combined were observed in treated females. In the rat study, no statistically significant increases in tumor findings were observed in either sex. The relevance of these liver tumor findings in mice to humans is not known. Because of tolerability of the formulation in these rodent studies, maximum systemic drug exposures achieved at the doses tested were lower than those in humans at the clinical dose (400 mg/day), with animal vs. human AUC ratios being 0.6-fold (mice) and 0.2-to-0.7-fold (rats). Mutagenesis Etravirine tested negative in the in vitro Ames reverse mutation assay, in vitro chromosomal aberration assay in human lymphocyte, and in vitro clastogenicity mouse lymphoma assay, tested in the absence and presence of a metabolic activation system. Etravirine did not induce chromosomal damage in the in vivo micronucleus test in mice. Impairment of Fertility No effects on fertility and early embryonic development were observed when etravirine was tested in rats at maternal doses up to 500 mg/day, resulting in systemic drug exposure up to the recommended human dose (400 mg/day).

13 NONCLINICAL TOXICOLOGY 13.1 Carcinogenesis, Mutagenesis, Impairment of Fertility Carcinogenesis Etravirine was evaluated for carcinogenic potential by oral gavage administration to mice and rats for up to approximately 104 weeks. Daily doses of 50 mg/kg, 200 mg/kg and 400 mg/kg were administered to mice and doses of 70 mg/kg, 200 mg/kg and 600 mg/kg were administered to rats in the initial period of approximately 41 to 52 weeks. The high and middle doses were subsequently adjusted due to tolerability and reduced by 50% in mice and by 50% to 66% in rats to allow for completion of the studies. In the mouse study, statistically significant increases in the incidences of hepatocellular carcinoma and incidences of hepatocellular adenomas or carcinomas combined were observed in treated females. In the rat study, no statistically significant increases in tumor findings were observed in either sex. The relevance of these liver tumor findings in mice to humans is not known. Because of tolerability of the formulation in these rodent studies, maximum systemic drug exposures achieved at the doses tested were lower than those in humans at the clinical dose (400 mg/day), with animal vs. human AUC ratios being 0.6-fold (mice) and 0.2-to-0.7-fold (rats). Mutagenesis Etravirine tested negative in the in vitro Ames reverse mutation assay, in vitro chromosomal aberration assay in human lymphocyte, and in vitro clastogenicity mouse lymphoma assay, tested in the absence and presence of a metabolic activation system. Etravirine did not induce chromosomal damage in the in vivo micronucleus test in mice. Impairment of Fertility No effects on fertility and early embryonic development were observed when etravirine was tested in rats at maternal doses up to 500 mg/day, resulting in systemic drug exposure up to the recommended human dose (400 mg/day).

ANDA214196

Etravirine

etravirine

60219-1722

HUMAN PRESCRIPTION DRUG

ORAL

PRINCIPAL DISPLAY PANEL NDC 60219-1720-7 Etravirine Tablets, 25 mg 120 Tablets Rx Only Amneal Pharmaceuticals LLC NDC 60219-1721-7 Etravirine Tablets, 100 mg 120 Tablets Rx Only Amneal Pharmaceuticals LLC NDC 60219-1722-6 Etravirine Tablets, 200 mg 60 Tablets Rx Only Amneal Pharmaceuticals LLC er 100 mg 200 mg

17 PATIENT COUNSELING INFORMATION Advise the patient to read the FDA-approved patient labeling (Patient Information). Administration Advise patients to take etravirine tablets following a meal twice a day on a regular dosing schedule, as missed doses can result in development of resistance. The type of food does not affect the exposure to etravirine. Inform patients not to take more or less than the prescribed dose of etravirine or discontinue therapy with etravirine without consulting their physician. Etravirine must always be used in combination with other antiretroviral drugs [see Dosage and Administration (2.4) ]. Advise patients to swallow the etravirine tablet(s) whole with a liquid such as water. Instruct patients not to chew the tablets. Patients who are unable to swallow the etravirine tablet(s) whole may disperse the tablet(s) in water. The patient should be instructed to do the following: place the tablet(s) in 5 mL (1 teaspoon) of water, or at least enough liquid to cover the medication, stir well until the water looks milky, add approximately 15 mL (1 tablespoon) of liquid. Water may be used, but orange juice or milk may improve taste. Patients should not place the tablets in orange juice or milk without first adding water. The use of warm (temperature greater than 104°F [greater than 40°C]) or carbonated beverages should be avoided. drink the mixture immediately, rinse the glass several times with orange juice, milk or water and completely swallow the rinse each time to make sure the patient takes the entire dose. Severe Skin Reactions Inform patients that severe and potentially life-threatening rash has been reported with etravirine. Rash has been reported most commonly in the first 6 weeks of therapy. Advise patients to immediately contact their healthcare provider if they develop rash. Instruct patients to immediately stop taking etravirine and seek medical attention if they develop a rash associated with any of the following symptoms as it may be a sign of a more serious reaction such as Stevens-Johnson syndrome, toxic epidermal necrolysis or severe hypersensitivity: fever, generally ill feeling, extreme tiredness, muscle or joint aches, blisters, oral lesions, eye inflammation, facial swelling, swelling of the eyes, lips, mouth, breathing difficulty, and/or signs and symptoms of liver problems (e.g., yellowing of your skin or whites of your eyes, dark or tea colored urine, pale colored stools/bowel movements, nausea, vomiting, loss of appetite, or pain, aching or sensitivity on your right side below your ribs). Patients should understand that if severe rash occurs, they will be closely monitored, laboratory tests will be ordered and appropriate therapy will be initiated [see Warnings and Precautions (5.1) ] . Drug Interactions Etravirine may interact with many drugs; therefore, advise patients to report to their healthcare provider the use of any other prescription or nonprescription medication or herbal products, including St. John's wort [see Warnings and Precautions (5.2) ] . Immune Reconstitution Syndrome Advise patients to inform their healthcare provider immediately of any symptoms of infection, as in some patients with advanced HIV infection (AIDS), signs and symptoms of inflammation from previous infections may occur soon after anti-HIV treatment is started [see Warnings and Precautions (5.3) ]. Fat Redistribution Inform patients that redistribution or accumulation of body fat may occur in patients receiving antiretroviral therapy, including etravirine, and that the cause and long-term health effects of these conditions are not known at this time [see Warnings and Precautions (5.4) ] . Pregnancy Registry Inform patients that there is an antiretroviral pregnancy registry to monitor fetal outcomes of pregnant individuals exposed to etravirine [see Use in Specific Populations (8.1) ] . Lactation Instruct mothers with HIV-1 infection not to breastfeed because HIV-1 can be passed to the baby in breast milk [see Use in Specific Populations (8.2) ] . All brands listed are trademark of their respective owner. Manufactured by: Amneal Pharmaceuticals Pvt. Ltd. Oral Solid Dosage Unit Ahmedabad 382213, INDIA Distributed by: Amneal Pharmaceuticals LLC Bridgewater, NJ 08807 Rev. 09-2023-02

14 CLINICAL STUDIES 14.1 Treatment-Experienced Adult Subjects The clinical efficacy of etravirine is derived from the analyses of 48-week data from 2 ongoing, randomized, double-blinded, placebo-controlled, Phase 3 trials, TMC125-C206 and TMC125-C216 (DUET-1 and DUET-2) in subjects with 1 or more NNRTI resistance-associated substitutions. These trials are identical in design and the results below are pooled data from the two trials. TMC125-C206 and TMC125-C216 are Phase 3 studies designed to evaluate the safety and antiretroviral activity of etravirine in combination with a background regimen (BR) as compared to placebo in combination with a BR. Eligible subjects were treatment-experienced HIV-1-infected subjects with plasma HIV-1 RNA greater than 5,000 copies/mL while on an antiretroviral regimen for at least 8 weeks. In addition, subjects had 1 or more NNRTI resistance-associated substitutions at screening or from prior genotypic analysis, and 3 or more of the following primary PI substitutions at screening: D30N, V32I, L33F, M46I/L, I47A/V, G48V, I50L/V, V82A/F/L/S/T, I84V, N88S, or L90M. Randomization was stratified by the intended use of ENF in the BR, previous use of darunavir/ritonavir, and screening viral load. Virologic response was defined as HIV-1 RNA less than 50 copies/mL at Week 48. All study subjects received darunavir/ritonavir as part of their BR, and at least 2 other investigator-selected antiretroviral drugs (N[t]RTIs with or without ENF). Of etravirine-treated subjects, 25.5% used ENF for the first time ( de novo ) and 20.0% re-used ENF. Of placebo-treated subjects, 26.5% used de novo ENF and 20.4% re-used ENF. In the pooled analysis for TMC125-C206 and TMC125-C216, demographics and baseline characteristics were balanced between the etravirine arm and the placebo arm (Table 13). Table 13 displays selected demographic and baseline disease characteristics of the subjects in the etravirine and placebo arms. Table 13: Demographic and Baseline Disease Characteristics of Subjects (Pooled Analysis TMC125-C206 and TMC125-C216)— Etravirine + BR N=599 Placebo + BR N=604 Demographic characteristics Median age, years (range) 46 (18 to 77) 45 (18 to 72) Sex Male 90.0% 88.6% Female 10.0% 11.4% Race White 70.1% 69.8% Black 13.2% 13.0% Hispanic 11.3% 12.2% Asian 1.3% 0.6% Other 4.1% 4.5% Baseline disease characteristics Median baseline plasma HIV-1 RNA (range), log 10 copies/mL 4.8 (2.7 to 6.8) 4.8 (2.2 to 6.5) Percentage of subjects with baseline viral load: < 30,000 copies/mL ≥ 30,000 copies/mL and < 100,000 copies/mL ≥ 100,000 copies/mL 27.5% 34.4% 38.1% 28.8% 35.3% 35.9% Median baseline CD4+ cell count (range), cells/mm 3 99 (1 to 789) 109 (0 to 912) Percentage of subjects with baseline CD4+ cell count: < 50 cells/mm 3 ≥ 50 cells/mm 3 and < 200 cells/mm 3 ≥ 200 cells/mm 3 35.6% 34.8% 29.6% 34.7% 34.5% 30.8% Median (range) number of primary PI substitutions * 4 (0 to 7) 4 (0 to 8) Percentage of subjects with previous use of NNRTIs: 0 1 > 1 8.2% 46.9% 44.9% 7.9% 46.7% 45.4% Percentage of subjects with previous use of the following NNRTIs: Efavirenz Nevirapine Delavirdine 70.3% 57.1% 13.7% 72.5% 58.6% 12.6% Median (range) number of NNRTI RASs † 2 (0 to 8) 2 (0 to 7) Median fold change of the virus for the following NNRTIs: Delavirdine Efavirenz Etravirine Nevirapine 27.3 63.9 1.6 74.3 26.1 45.4 1.5 74.0 Percentage of subjects with previous use of a fusion inhibitor 39.6% 42.2% Percentage of subjects with a Phenotypic Sensitivity Score (PSS) for the background therapy ‡ of: 0 1 2 ≥ 3 17.0% 36.5% 26.9% 19.7% 16.2% 38.7% 27.8% 17.3% RASs = Resistance-Associated Substitutions, BR=background regimen, FC = fold change in EC 50 * IAS-USA primary PI substitutions [August/September 2007]: D30N, V32I, L33F, M46I/L, I47A/V, G48V, I50L/V, I54L/M, L76V, V82A/F/L/S/T, I84V, N88S, L90M † Tibotec NNRTI RASs [June 2008]: A98G, V90I, L100I, K101E/H/P/Q, K103H/N/S/T, V106A/M/I, V108I, E138A/G/K/Q, V179D/E/F/G/I/T, Y181C/I/V, Y188C/H/L, V189I, G190A/C/E/Q/S, H221Y, P255H, F227C/L, M230I/L, P236L, K238N/T, Y318F ‡ The PSS was calculated for the background therapy (as determined on Day 7). Percentages are based on the number of subjects with available phenotype data. For fusion inhibitors (enfuvirtide), subjects were considered resistant if the drug was used in previous therapy up to baseline. Etravirine is not included in this calculation. Efficacy at Week 48 for subjects in the etravirine and placebo arms for the pooled TMC125-C206 and TMC125-C216 study populations are shown in Table 14. Table 14: Treatment Outcomes at Week 48 (Pooled Analysis TMC125-C206 and TMC125-C216) Etravirine + BR N=599 Placebo + BR N=604 Virologic responders at Week 48 Viral Load < 50 HIV-1 RNA copies/mL 359 (60%) 232 (38%) Virologic failures at Week 48 Viral Load ≥ 50 HIV-1 RNA copies/mL 123 (21%) 201 (33%) Death 11 (2%) 19 (3%) Discontinuations before Week 48: due to virologic failures 58 (10%) 110 (18%) due to adverse events 31 (5%) 14 (2%) due to other reasons 17 (3%) 28 (5%) BR=background regimen At Week 48, 70.8% of etravirine-treated subjects achieved HIV-1 RNA less than 400 copies/mL as compared to 46.4% of placebo-treated subjects. The mean decrease in plasma HIV-1 RNA from baseline to Week 48 was -2.23 log 10 copies/mL for etravirine-treated subjects and -1.46 log 10 copies/mL for placebo-treated subjects. The mean CD4+ cell count increase from baseline for etravirine-treated subjects was 96 cells/mm 3 and 68 cells/mm 3 for placebo-treated subjects. Of the study population who either re-used or did not use ENF, 57.4% of etravirine-treated subjects and 31.7% of placebo-treated subjects achieved HIV-1 RNA less than 50 copies/mL. Of the study population using ENF de novo, 67.3% of etravirine-treated subjects and 57.2% of placebo-treated subjects achieved HIV-1 RNA less than 50 copies/mL. Treatment-emergent CDC category C events occurred in 4% of etravirine-treated subjects and 8.4% of placebo-treated subjects. Study TMC125-C227 was a randomized, exploratory, active-controlled, open-label, Phase 2b trial. Eligible subjects were treatment-experienced, PI-naïve HIV-1-infected subjects with genotypic evidence of NNRTI resistance at screening or from prior genotypic analysis. The virologic response was evaluated in 116 subjects who were randomized to etravirine (59 subjects) or an investigator-selected PI (57 subjects), each given with 2 investigator-selected N(t)RTIs. Etravirine-treated subjects had lower antiviral responses associated with reduced susceptibility to the N(t)RTIs and to etravirine as compared to the control PI-treated subjects. 14.2 Treatment-Experienced Pediatric Subjects (6 Years to Less Than 18 Years of Age) The efficacy of etravirine for treatment-experienced pediatric subjects is based on one Phase 2 trial, TMC125-C213. Pediatric Subjects (6 Years to Less Than 18 Years of Age [TMC125-C213]) TMC125-C213, a single-arm, Phase 2 trial evaluating the pharmacokinetics, safety, tolerability, and efficacy of etravirine enrolled 101 antiretroviral treatment-experienced HIV-1 infected pediatric subjects 6 years to less than 18 years of age and weighing at least 16 kg. Subjects eligible for this trial were on an antiretroviral regimen with confirmed plasma HIV-1 RNA of at least 500 copies/mL and viral susceptibility to etravirine at screening. The median baseline plasma HIV-1 RNA was 3.9 log 10 copies/mL, and the median baseline CD4+ cell count was 385 x 10 6 cells/mm 3 . At Week 24, 52% of subjects had HIV-1 RNA less than 50 copies per mL. The proportion of subjects with HIV-1 RNA less than 400 copies/mL was 67%. The mean CD4+ cell count increase from baseline was 112 x 10 6 cells/mm 3 . Additional pediatric use information is approved for Janssen Products, LP’s INTELENCE ® (etravirine) tablets. However, due to Janssen Products, LP’s marketing exclusivity rights, this drug product is not labeled with that pediatric information.

8.5 Geriatric Use Clinical studies of etravirine did not include sufficient numbers of subjects aged 65 years of age and over to determine whether they respond differently from younger subjects. Other reported clinical experience has not identified differences in responses between the elderly and younger subjects. In general, dose selection for an elderly patient should be cautious, reflecting the greater frequency of decreased hepatic, renal, or cardiac function, and of concomitant disease or other drug therapy [see Clinical Pharmacology (12.3) ] .

8.2 Lactation Risk Summary The Centers for Disease Control and Prevention recommend that HIV-1-infected mothers not breastfeed their infants to avoid risking postnatal transmission of HIV. Based on limited data, etravirine has been shown to be present in human breast milk. There are no data on the effects of etravirine on the breastfed infant, or the effects of etravirine on milk production. Because of the potential for (1) HIV-1 transmission (in HIV-negative infants), (2) developing viral resistance (in HIV-positive infants) and (3) adverse reactions in breastfed infants similar to those seen in adults, instruct mothers not to breastfeed if they are receiving etravirine.

8.4 Pediatric Use The safety and effectiveness of etravirine have been established for the treatment of HIV-infected pediatric patients from 6 years of age to less than 18 years [see Indications and Usage (1) and Dosage and Administration (2.3) ] . Use of etravirine in pediatric patients 6 years to less than 18 years of age is supported by evidence from adequate and well-controlled studies of etravirine in adults with additional data from a Phase 2 trial in treatment-experienced pediatric subjects, TMC125-C213, 6 years to less than 18 years of age (N=101). The study was an open-label, single arm trial of etravirine plus an optimized background regimen. In the clinical trial, the safety, pharmacokinetics, and efficacy were comparable to that observed in adults except for rash (greater than or equal to Grade 2) which was observed more frequently in pediatric subjects [see Adverse Reactions (6.1) , Clinical Pharmacology (12.3) , and Clinical Studies (14.2) ] . Postmarketing reports of Stevens-Johnson syndrome in pediatric patients receiving etravirine have been reported [see Warnings and Precautions (5.1) , and Adverse Reactions (6.2) ]. Treatment with etravirine is not recommended in pediatric patients less than 2 years of age [see Clinical Pharmacology (12.3) ] . Additional pediatric use information is approved for Janssen Products, LP’s INTELENCE ® (etravirine) tablets. However, due to Janssen Products, LP’s marketing exclusivity rights, this drug product is not labeled with that pediatric information.

8.1 Pregnancy Pregnancy Exposure Registry There is a pregnancy exposure registry that monitors pregnancy outcomes in individuals exposed to etravirine during pregnancy. Healthcare providers are encouraged to register patients by calling the Antiretroviral Pregnancy Registry (APR) at 1-800-258-4263. Risk Summary Prospective pregnancy data from clinical trials and the APR are not sufficient to adequately assess the risk of major birth defects, miscarriage or adverse maternal or fetal outcomes. Etravirine use during pregnancy has been evaluated in a limited number of individuals as reported by the APR, and available data show 1 birth defect in 66 first trimester exposures to etravirine-containing regimens (see Data) . The estimated background rate for major birth defects is 2.7% in the U.S. reference population of the Metropolitan Atlanta Congenital Defects Program (MACDP). The rate of miscarriage is not reported in the APR. The estimated background rate of miscarriage in clinically recognized pregnancies in the U.S. general population is 15% to 20%. The background risk of major birth defects and miscarriage for the indicated population is unknown. In animal reproduction studies, no adverse developmental effects were observed with orally administered etravirine at exposures equivalent to those at the maximum recommended human dose (MRHD) of 400 mg daily (see Data) . Data Human Data Based on prospective reports to the APR of 116 live births following exposure to etravirine-containing regimens during pregnancy (including 66 exposed in the first trimester and 38 exposed in the second/third trimester), the number of birth defects in live births for etravirine was 1 out of 66 with first trimester exposure and 0 out of 38 with second/third trimester exposure. Prospective reports from the APR of overall major birth defects in pregnancies exposed to etravirine are compared with a U.S. background major birth defect rate. Methodological limitations of the APR include the use of MACDP as the external comparator group. Limitations of using an external comparator include differences in methodology and populations, as well as confounding due to the underlying disease; these limitations preclude an accurate comparison of outcomes. Etravirine (200 mg twice daily) in combination with other antiretroviral agents was evaluated in a clinical trial enrolling 15 pregnant subjects during the second and third trimesters of pregnancy and postpartum. Thirteen subjects completed the trial through postpartum period (6 to 12 weeks after delivery). The pharmacokinetic data demonstrated that exposure to total etravirine was generally higher during pregnancy compared with postpartum [see Clinical Pharmacology (12.3) ] . Among subjects who were virologically suppressed (HIV-1 RNA less than 50 copies/mL) at baseline (9/13), virologic suppression was maintained through the third trimester and postpartum period. Among subjects with HIV-1 RNA greater than 50 copies/mL and less than 400 copies/mL at baseline (3/13), viral loads remained less than 400 copies/mL. In one subject with HIV-1 RNA greater than 1,000 copies/mL at baseline (1/13), HIV-1 RNA remained greater than 1,000 copies/mL during the study period. Thirteen infants were born to 13 HIV-infected pregnant individuals in this study. HIV-1 test results were not available for 2 infants. Among the eleven infants with HIV-1 test results available, who were born to 11 HIV-infected pregnant individuals who completed the study, all had test results that were negative for HIV-1 at the time of delivery. No unexpected safety findings were observed compared with the known safety profile of etravirine in non-pregnant adults. Animal Data Reproductive and developmental toxicity studies were performed in rats (at 250, 500 and 1,000 mg/kg/day) and rabbits (at 125, 250 and 375 mg/kg/day) administered etravirine on gestation days 6 through 16, and 6 through 19, respectively. In both species, no treatment-related embryo-fetal effects were observed. In addition, no treatment-related effects were observed in a pre- and postnatal development study performed in rats administered oral doses up to 500 mg/kg/day on gestation days 7 through lactation day 7. The systemic drug exposures achieved at the high dose in these animal studies were equivalent to those at the MRHD.

8 USE IN SPECIFIC POPULATIONS Lactation: Breastfeeding is not recommended due to the potential for HIV-1 transmission. (8.2) Additional pediatric use information is approved for Janssen Products, LP’s INTELENCE ® (etravirine) tablets. However, due to Janssen Products, LP’s marketing exclusivity rights, this drug product is not labeled with that pediatric information. 8.1 Pregnancy Pregnancy Exposure Registry There is a pregnancy exposure registry that monitors pregnancy outcomes in individuals exposed to etravirine during pregnancy. Healthcare providers are encouraged to register patients by calling the Antiretroviral Pregnancy Registry (APR) at 1-800-258-4263. Risk Summary Prospective pregnancy data from clinical trials and the APR are not sufficient to adequately assess the risk of major birth defects, miscarriage or adverse maternal or fetal outcomes. Etravirine use during pregnancy has been evaluated in a limited number of individuals as reported by the APR, and available data show 1 birth defect in 66 first trimester exposures to etravirine-containing regimens (see Data) . The estimated background rate for major birth defects is 2.7% in the U.S. reference population of the Metropolitan Atlanta Congenital Defects Program (MACDP). The rate of miscarriage is not reported in the APR. The estimated background rate of miscarriage in clinically recognized pregnancies in the U.S. general population is 15% to 20%. The background risk of major birth defects and miscarriage for the indicated population is unknown. In animal reproduction studies, no adverse developmental effects were observed with orally administered etravirine at exposures equivalent to those at the maximum recommended human dose (MRHD) of 400 mg daily (see Data) . Data Human Data Based on prospective reports to the APR of 116 live births following exposure to etravirine-containing regimens during pregnancy (including 66 exposed in the first trimester and 38 exposed in the second/third trimester), the number of birth defects in live births for etravirine was 1 out of 66 with first trimester exposure and 0 out of 38 with second/third trimester exposure. Prospective reports from the APR of overall major birth defects in pregnancies exposed to etravirine are compared with a U.S. background major birth defect rate. Methodological limitations of the APR include the use of MACDP as the external comparator group. Limitations of using an external comparator include differences in methodology and populations, as well as confounding due to the underlying disease; these limitations preclude an accurate comparison of outcomes. Etravirine (200 mg twice daily) in combination with other antiretroviral agents was evaluated in a clinical trial enrolling 15 pregnant subjects during the second and third trimesters of pregnancy and postpartum. Thirteen subjects completed the trial through postpartum period (6 to 12 weeks after delivery). The pharmacokinetic data demonstrated that exposure to total etravirine was generally higher during pregnancy compared with postpartum [see Clinical Pharmacology (12.3) ] . Among subjects who were virologically suppressed (HIV-1 RNA less than 50 copies/mL) at baseline (9/13), virologic suppression was maintained through the third trimester and postpartum period. Among subjects with HIV-1 RNA greater than 50 copies/mL and less than 400 copies/mL at baseline (3/13), viral loads remained less than 400 copies/mL. In one subject with HIV-1 RNA greater than 1,000 copies/mL at baseline (1/13), HIV-1 RNA remained greater than 1,000 copies/mL during the study period. Thirteen infants were born to 13 HIV-infected pregnant individuals in this study. HIV-1 test results were not available for 2 infants. Among the eleven infants with HIV-1 test results available, who were born to 11 HIV-infected pregnant individuals who completed the study, all had test results that were negative for HIV-1 at the time of delivery. No unexpected safety findings were observed compared with the known safety profile of etravirine in non-pregnant adults. Animal Data Reproductive and developmental toxicity studies were performed in rats (at 250, 500 and 1,000 mg/kg/day) and rabbits (at 125, 250 and 375 mg/kg/day) administered etravirine on gestation days 6 through 16, and 6 through 19, respectively. In both species, no treatment-related embryo-fetal effects were observed. In addition, no treatment-related effects were observed in a pre- and postnatal development study performed in rats administered oral doses up to 500 mg/kg/day on gestation days 7 through lactation day 7. The systemic drug exposures achieved at the high dose in these animal studies were equivalent to those at the MRHD. 8.2 Lactation Risk Summary The Centers for Disease Control and Prevention recommend that HIV-1-infected mothers not breastfeed their infants to avoid risking postnatal transmission of HIV. Based on limited data, etravirine has been shown to be present in human breast milk. There are no data on the effects of etravirine on the breastfed infant, or the effects of etravirine on milk production. Because of the potential for (1) HIV-1 transmission (in HIV-negative infants), (2) developing viral resistance (in HIV-positive infants) and (3) adverse reactions in breastfed infants similar to those seen in adults, instruct mothers not to breastfeed if they are receiving etravirine. 8.4 Pediatric Use The safety and effectiveness of etravirine have been established for the treatment of HIV-infected pediatric patients from 6 years of age to less than 18 years [see Indications and Usage (1) and Dosage and Administration (2.3) ] . Use of etravirine in pediatric patients 6 years to less than 18 years of age is supported by evidence from adequate and well-controlled studies of etravirine in adults with additional data from a Phase 2 trial in treatment-experienced pediatric subjects, TMC125-C213, 6 years to less than 18 years of age (N=101). The study was an open-label, single arm trial of etravirine plus an optimized background regimen. In the clinical trial, the safety, pharmacokinetics, and efficacy were comparable to that observed in adults except for rash (greater than or equal to Grade 2) which was observed more frequently in pediatric subjects [see Adverse Reactions (6.1) , Clinical Pharmacology (12.3) , and Clinical Studies (14.2) ] . Postmarketing reports of Stevens-Johnson syndrome in pediatric patients receiving etravirine have been reported [see Warnings and Precautions (5.1) , and Adverse Reactions (6.2) ]. Treatment with etravirine is not recommended in pediatric patients less than 2 years of age [see Clinical Pharmacology (12.3) ] . Additional pediatric use information is approved for Janssen Products, LP’s INTELENCE ® (etravirine) tablets. However, due to Janssen Products, LP’s marketing exclusivity rights, this drug product is not labeled with that pediatric information. 8.5 Geriatric Use Clinical studies of etravirine did not include sufficient numbers of subjects aged 65 years of age and over to determine whether they respond differently from younger subjects. Other reported clinical experience has not identified differences in responses between the elderly and younger subjects. In general, dose selection for an elderly patient should be cautious, reflecting the greater frequency of decreased hepatic, renal, or cardiac function, and of concomitant disease or other drug therapy [see Clinical Pharmacology (12.3) ] . 8.6 Hepatic Impairment No dose adjustment of etravirine is required in patients with mild (Child-Pugh Class A) or moderate (Child-Pugh Class B) hepatic impairment. The pharmacokinetics of etravirine have not been evaluated in patients with severe hepatic impairment (Child-Pugh Class C) [see Clinical Pharmacology (12.3) ] . 8.7 Renal Impairment Since the renal clearance of etravirine is negligible (less than 1.2%), a decrease in total body clearance is not expected in patients with renal impairment. No dose adjustments are required in patients with renal impairment. As etravirine is highly bound to plasma proteins, it is unlikely that it will be significantly removed by hemodialysis or peritoneal dialysis [see Clinical Pharmacology (12.3) ] .

16 HOW SUPPLIED/STORAGE AND HANDLING Etravirine Tablets, 25 mg are supplied as white to off-white, oval shaped, uncoated tablets containing 25 mg of etravirine. Each tablet is debossed with “A56” on one side and score on the other side. They are available as follows: Bottles of 120 with child-resistant closure: NDC 60219-1720-7 Each bottle contains 2 desiccant pouches. Etravirine Tablets, 100 mg are supplied as white to off-white, oval shaped, uncoated tablets containing 100 mg of etravirine. Each tablet is debossed with “AC75” on one side and plain on the other side. They are available as follows: Bottles of 120 with child-resistant closure: NDC 60219-1721-7 Each bottle contains 3 desiccant pouches. Etravirine Tablets, 200 mg are supplied as white to off-white, oval shaped, uncoated tablets containing 200 mg of etravirine. Each tablet is debossed with “AC76” on one side and plain on the other side. They are available as follows: Bottles of 60 with child-resistant closure: NDC 60219-1722-6 Each bottle contains 3 desiccant pouches. Store etravirine tablets at 20° to 25°C (68° to 77°F); excursions permitted between 15° to 30°C (59° to 86°F) [see USP controlled room temperature]. Store in the original bottle. Keep the bottle tightly closed in order to protect from moisture. Do not remove the desiccant pouches.